{
  "name" : "dacemirror.sci-hub.se_journal-article_236fe954e47df76c882c03302872b3bf_ema2017.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "A review of toxicity studies on graphene-based nanomaterials in laboratory animals",
    "authors" : [ "Makoto Ema", "Masashi Gamo", "Kazumasa Honda" ],
    "emails" : [ "ema-makoto@aist.go.jp" ],
    "sections" : [ {
      "heading" : null,
      "text" : "lable at ScienceDirect\nContents lists avai\nRegulatory Toxicology and Pharmacology\njournal homepage: www.elsevier .com/locate/yrtph\nA review of toxicity studies on graphene-based nanomaterials in laboratory animals\nMakoto Ema*, Masashi Gamo, Kazumasa Honda Research Institute of Science for Safety and Sustainability, National Institute of Advanced Industrial Science and Technology (AIST) and Technology Research Association for Single Wall Carbon Nanotubes (TASC), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan\na r t i c l e i n f o\nArticle history: Received 1 August 2016 Received in revised form 10 November 2016 Accepted 27 January 2017 Available online 1 February 2017\nKeywords: Graphene-based nanomaterials Graphene Graphene oxide Reduced graphene oxide Graphene quantum dots Toxicity Inflammation Biodistribution In vivo\nAbbreviations: Ach, acetylcholine; ADD, aerodynam alanine aminotransferase; AST, aspartate aminotransf balanced salty solution; BUN, blood urea nitrogen; CD using apparent density; CINC, cytokine-induced neu diameter; DEX-, dextran functionalized; ED, exposure day; GGT, g-glutamyl transpeptidase; GLP, good labora graphene oxide; GP, graphene; GQD, graphene quantu hydrodynamic diameter; HDS, hydrodynamic size; H lactobinoic acid-polyethylene glycol functionalized; LD chemotactic protein; MDA, malondialdehyde; MIP, ma micronuleated polychromatic erythrocyte; MWCNT, m alized; OH-, hydroxyl; PAA-, poly(acrylic acid)-funct erythrocytes to normochromatic erythrocytes; PEI-, p PLT, platelet; PMNs, polymorphonuclear leucocytes; PN rGO, reduced graphene oxide; ROS, reactive oxygen sp walled carbon nanotube; Sh, size in H2O; SOD, supero factor; TLR, toll-like receptor; TNF, tumor necrosis fac * Corresponding author. Tel.: þ81 29 861 8021; fax\nE-mail address: ema-makoto@aist.go.jp (M. Ema).\nhttp://dx.doi.org/10.1016/j.yrtph.2017.01.011 0273-2300/© 2017 Elsevier Inc. All rights reserved.\na b s t r a c t\nWe summarized the findings of toxicity studies on graphene-based nanomaterials (GNMs) in laboratory mammals. The inhalation of graphene (GP) and graphene oxide (GO) induced only minimal pulmonary toxicity. Bolus airway exposure to GP and GO caused acute and subacute pulmonary inflammation. Largesized GO (L-GO) was more toxic than small-sized GO (S-GO). Intratracheally administered GP passed through the air-blood barrier into the blood and intravenous GO distributed mainly in the lungs, liver, and spleen. S-GO and L-GO mainly accumulated in the liver and lungs, respectively. Limited information showed the potential behavioral, reproductive, and developmental toxicity and genotoxicity of GNMs. There are indications that oxidative stress and inflammation may be involved in the toxicity of GNMs. The surface reactivity, size, and dispersion status of GNMs play an important role in the induction of toxicity and biodistribution of GNMs. Although this review paper provides initial information on the potential toxicity of GNMs, data are still very limited, especially when taking into account the many different types of GNMs and their potential modifications. To fill the data gap, further studies should be performed using laboratory mammals exposed using the route and dose anticipated for human exposure scenarios.\n© 2017 Elsevier Inc. All rights reserved.\n1. Introduction\nHumans are continually exposed to naturally occurring nanoparticles. In addition, the rapidly developing field of\nic diameter; AgD, agglomerate den erase; BALF, bronchoalveolar lavag D, cumulative deposition dose; CDA trophil chemoattractant; COOH-, dose; ENM, engineered nanomate tory practice; GM-CSF, granulocyte m dot; GSD, geometric standard d GB, hemoglobin; ICP-MS, inducti , lateral dimension; LDH, lactate de crophage inflammatory protein; M ulti-walled carbon nanotube; N2ionalized; PAM-, poly(acrylamide olyethylenimine functionalized; PE D, postnatal day; PSS-, sodium 4-s ecies; S, size; S-, small-sized; SA, su xide dismutase; T, thickness; TAT, t tor; TUNEL, TdT-mediated dUTP n : þ81 29 861 8904.\nnanotechnology, which is creating materials with size-dependent properties. Actually it already became a source of exposure, considering the growing number of engineered nanomaterial (ENM) occupational exposure assessment studies. The ENMs have\nsity; AgS, Agglomerate size; ApD, apparent density; ALP, alkaline phosphatase; ALT, e fluid; BBS, balanced buffer solution; BSA(-), bovine serum albumin(-coated); BSS, gD, calculated deposition using agglomerate density; CDApD, calculated deposition carboxylated; CRE, creatinine; CSAg/P, cross section of agglomerates/particles; D, rial; EHD, equivalent hydrodynamic diameter; Fc-, F functionalized; GD, gestational macrophage colony-stimulating factor; GNMs, graphene-based nanomaterials; GO, eviation; GSH, glutathione; GSH-PX, glutathione peroxidase; HCT, hematocrit; HDD, vely-coupled plasma mass spectrometry; IL, interleukin; L-, large-sized; LA-PEG-, hydrogenase; MCHC, mean corpuscular hemoglobin concentration; MCP, monocyte MAD, mass median aerodynamic diameter; MMP, matrix metallopeptidase; MNPCE, , acylated; NF, nuclear factor; NH2-, aminated; NM, nanomaterial; O2-, Oþ fuction)-fuctionalized; PBS, phosphate-buffered saline; PCE/NCE, ratio of polychromatic G-, polyethylene glycol functionalized; PF-, PF108-dispersed; PL, peritoneal lavage; tyrenesulfonate functionalized; RBC, red blood cell; RES, reticuloendothelial system; rface area; SA-BET, surface area by Brunauer-Emmett-Teller method; SWCNT, singlehrombin-antithrombin; TEM, transmission electron microscope; TGF, tumor growth ick end labeling; WBC, white blood cell; ZP, zeta potential.\nan increased surface area:mass ratio, greatly enhancing their chemical/catalytic reactivity compared with normal-sized forms of the same substance. Human exposure can occur at any stage during the life cycle, including the synthesis, manufacture, use, and disposal, of ENMs (Jim enez et al., 2014). The introduction of these novel materials into the work environment and consumer products necessitates safety evaluations as well as a clearer understanding of any potential impact on human health. Nanomaterials (NMs) have the ability to pass through biological membranes (RothenRutishauser et al., 2007); therefore, they may be able to affect the physiology of any cell in the body. The potential of chemicals to enter biological systems is a matter of great concern to the general public. At present, however, information on the toxicological effects of ENMs is very limited.\nGraphene (GP) is the new allotrope of carbon and is defined as a single layer of monocrystalline graphite with sp2-hybridized carbon atoms tightly packed in a two-dimensional honeycomb lattice, resulting in a large surface area on both sides of the planar axis (Duch et al., 2011; Bianco, 2013; Seabra et al., 2014). GP-based NMs (GNMs) include single-layer GP, few-layer GP (2e10 layers), GP oxide (GO) (normally a single layer), reduced GO (rGO) (normally a single layer), GP nanosheets, GP ribbons, and GP quantum dots (GQDs) (Sanchez et al., 2012; Bianco, 2013). GNMs have unique electronic andmechanical properties, specificmagnetism, excellent mobility of charge carriers, high thermal conductivity, a large surface area, excellent conductivity, outstanding mechanical strength, and extraordinary electrocatalytic activity (Jastrzębska et al., 2012), as well as potential biocompatibility, which make them attractive candidates for biomedical applications including electrochemical devices, energy storage, absorption of enzymes, cell imaging, drug delivery, and biosensors (Xu et al., 2013).\nGNMs are newly developed substances; single GP layers were first isolated by the mechanical exfoliation of highly oriented\npyrolytic graphite (Novoselov et al., 2004). To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016). However, these review papers provided insufficient information about in vivo toxicity studies using mammalian species because toxicity studies of GNMs have been rarely performed until very recently and the amount of literature on this topic has only just started to increase. It is very important, from time to time, to take a break and summarize and re-assess the accumulating data, because ongoing and future research alongwith new findings are the only productive ways to assess risks and potential hazards associated with the use of newmaterials (Shvedova et al., 2016). In this review, we focused on the significant toxic effects of GNMs, published as openly available scientific literature, in laboratory mammals because the use of mammalian species is essential for the realistic testing of toxicity. The objective of this review is to evaluate what is currently known about the toxicity of GNMs and to understand the potential risk posed by them.\n2. Data from animal research\n2.1. Pulmonary toxicity\n2.1.1. Pulmonary toxicity in rats exposed by inhalation Four nose-only inhalation studies are available on the pulmonary toxicity of GP and GO (Table 1). Rats inhaled GP at 0.54, 3.05, or 10.1 mg/m3 for consecutive 5 days, 6 h/day (Ma-Hock et al., 2013). Test atmospheres with GP were producedwith swinging bed dust generator. Generation dusts were mixed with compressed air in a glass tube, diluted with conditioned air and passed via a cyclone into the inhalation system. The aerodynamic diameters of the agglomerates were mostly\ny inhalation.\nbetween 1 and 2 mm. Inflammatory changes were observed in cytology and enzyme activity in the bronchoalveolar fluid (BALF) of rats exposed to GP at 3.05 and 10.1 mg/m3. Histopathological examinations of the lungs revealed the particle-ladenmacrophages or aggregates of macrophages and a single or few microgranulomas (diagnosed as granulomatous inflammation) in the lung tissues of rats exposed to GP at 3.05 and 10.1mg/m3. More severe toxicity was observed on day 7 and slightly recovered on day 28 after inhalation. The authors noted that the lung toxicity of GP at 10.1 mg/m3 was less severe than that of multi-walled carbon nanotubes (MWCNTs) at 2.86 mg/m3 and concluded that hat neither differences in the mesoscopic structure of the nanomaterials nor differences in the lung burden correlated well the differences in toxicity.\nRats inhaled GP for 5 days, 6 h/day (Shin et al., 2015). The GP nanopowder was generated using an atomizer, and purified air used as the carrier gas. The suspension contained 50 mg/mL for the high concentration, and 5 mg/mL for the low concentration. The particle size ranged from 10 to 130 nm, with the highest peak at 50 nm and 80 nm for the low and high concentration, respectively. Minor changes were observed in the neutrophils, lymphocytes, white blood cells (WBCs), and mean corpuscular hemoglobin concentration (MCHC) at 3.86 mg/m3. Although a slight thickening of the alveolar wall was observed at 3.86 mg/m3 until day 11, no significant pathological changes were detected either at 0.68 or 3.86 mg/m3 on day 32. Alveolar macrophages that had ingested GP were observed at 0.68 and 3.86mg/m3 until day 32. Estimated daily (cumulative) deposited doses were 0.0036 (0.018) and 0.0203 (0.102) mg/rat at 0.68 and 3.86 mg/m3, respectively. The authors suggest that the 5-day repeated inhalation of GP has a minimal toxic effect on male rats.\nRats inhaled GP for 4 weeks, 6 h/day and 5 days/week (Kim et al., 2016). The GP nanopowder was generated using an atomizer, with purified air as the carrier gas. The suspension in water used to generate the aerosol contained 1.5 mg/mL for the low concentration, 5 mg/mL for the moderate concentration, and 16 mg/mL for the high concentration. No concentration-dependent effects of GP on the body weight, organ weight, BALF inflammatory parameters, or blood chemistry were observed. Estimated daily (cumulative) deposited doses were 0.0006 (0.012), 0.0025 (0.05), and 0.0099 (0.198) mg/rat at 0.12, 0.47, and 1.88 mg/m3, respectively.\nRats exposed to a single 6-h inhalation of GO (Han et al., 2015). The GO was generated using an atomizer, with purified air as the carrier gas. The particle size ranged from 10 to 120 nm, with the highest peak at 35 nm and 50 nm for the low and high concentration, respectively. GO did not exhibit toxicological effects, except for increased levels of matrix metalloproteinase (MMP)-9 and tumor growth factor (TGF)-b1 in BALF at 3.76 mg/m3. During the histological assessment, alveolar macrophages that had ingested GO were visualized at 3.76 mg/m3 on days 1e14. Estimated deposited doses were 0.003 and 0.026 mg/rat at 0.46 and 3.76 mg/ m3, respectively. The authors suggest that a single 6-h exposure to GO has a minimal toxic effect on male rats.\nOverall, inhalations of GP and GO induced reversibly minimal pulmonary toxicity/inflammation in male rats.\n2.1.2. Pulmonary toxicity in mice exposed by intratracheal instillation or pharyngeal aspiration\nTable 2 summarizes studies on pulmonary toxicity of GP and GO following exposure by a single intratracheal instillation, pharyngeal aspiration, and intrapleural injection in mice.\nMice received the intratracheal instillation of aggregated or dispersed GP or GO and their toxic outcomes were compared (Duch et al., 2011). Aggregated GP inwater was vortexed and sonicated for 10 min prior to instillation and dispersed GP and GO solutions were vortexed immediately prior to instillation. Both GPs caused\nminimal pulmonary inflammation, and dispersed GP had a slightly weaker toxicity than aggregated GP. Aggregated GP persisted in the lung and induced peribronchial inflammation andmild fibrosis, but dispersed GP did not induce lung fibrosis. However, GO induced severe lung injury including an increase in BALF levels of proinflammatory cytokines and apoptotic cells, and disruption of the alveolar-capillary barrier. Persistent lung inflammation was observed on 21 day after instillation of GO, but there was little evidence of fibrosis. GO increased the generation of mitochondrial reactive oxygen species (ROS) in an in vitro assay. The authors noted that the dispersion of GP might reduce the potential toxicity.\nIncreased levels of pro-inflammatory cytokines were observed in BALF of mice with intratracheal instillation of GP nanoplatelets (Park et al., 2015). Inflammatory responses reached maximal levels at 14 days after instillation and then decreased over time. GP was retained in the lungs until 28 days after instillation. The authors reported that GP induced subacute inflammatory responses in the lungs.\nMice were administered GP by intratracheal instillation (Mao et al., 2016). Prior to instillation, GP solutions were re-dispersed using ultrasonication for 30 min. Inflammatory responses in BALF, and moderate interstitial and parenchymal edema and macrophages in the alveoli were observed at 24 h after instillation. The severity was decreased on day 7 and no pathological changes in the lungs were observed on day 28 despite 47% of the initial dose of GP being retained in the lung. The authors noted that intratracheal GP induced transient acute pulmonary injury.\nThe role of surface functionalization in pulmonary inflammation was evaluated using 6 types of GPs: GP, carboxylated GP (COOHGP), Oþ functionalized GP (O2-GP, acylated GP (N2-GP), F functionalized GP (Fc GP), and aminated GP (NH2-GP), intratracheally instilled in rats (Lee et al., 2016). GP was deposited on the outside of cells and inside of phagocytes at 24 h and in the lymph nodes at 4 weeks after instillation. At 24 h after instillation, multifocal alveolitis was observed with variable severity: moderate for GP and O2-, N2-, and NH2-GP, and minimal to moderate for COOH- and Fc GP. Pulmonary fibrosis andmononuclear cell infiltrationwere observed at 1 week and fibrosis was observed at 4 weeks. BAF levels of LDH were increased after instillation of COOH-, O2-, N2-, and Fc GP at 24 h, O2-, N2-, Fc-, and NH2-GP at 1 week, and GP and COOH-, O2-, N2-, Fc-, and NH2-GP at 4 weeks. In the cell-free assay system, all types of GPs dose-dependently increased ROS generation at comparable levels. The authors noted that positively charged GPs (N2and NH2-GO) induced slightly more marked inflammation.\nMice received the pharyngeal aspiration or intrapleural injection of GP (Schinwald et al., 2012). GP solution was dispersed by sonication in an ultrasonicating water bath for 6 h to break up aggregates. After pharyngeal aspiration of GP, inflammatory responses were observed in the BALF and lungs, and inflammation in the lungs on day 7 was less significant compared with that on day 1. After intrapleural injection of GP, inflammatory responses were induced in pleural lavage and pleura. Rosette-like formations of macrophages around GP indicating frustrated phagocytosis were observed. Inflammatory responses on the mesothelial layer of the parietal pleura and pleural thickening were also found. However, acute inflammation was largely resolved 7 days after injection of GP. The authors suggest that GP is not fully biopersistent, and is cleared slowly to the mediastinal lymph nodes.\nMice were administered GP by pharyngeal aspiration of GP (Schinwald et al., 2014). GP solution was dispersed by sonication in an ultrasonicating water bath for 6 h to break up aggregates. No inflammatory responses were observed in the BALF or lungs at 6 weeks nor in the pleura up to 6 weeks after aspiration. GP was not degraded or deposited in the lung. No accumulation of GP was observed in the sub-pleural tissue, and no inflammation was found\nTable 2 (continued )\nTest materials Dosing solutions Animals (No. of animals/ group) Exposure Observation after exposure Findings Reference Routes Doses\nBAS-GP (D: 640 nm, ZP: 27.1 mV, Sh: 1179 nm), PF-GP (D: 45 nm, ZP: 8.7 mV, Sh: 236 nm), S-GO (D: 179 nm, ZP: 30.9 mV, Sh: 330 nm), LGO (D: 1676 nm, ZP: 14.8 mV, Sh: 2007 nm) GP/GO in PBS Male C57BL/6 mice PA (single) 50 mg/ mouse 40 h, 21 days [ IL-b1 and total cell count at 40 h and TGF-b1 in BALF at 21 days after PA of BSAGP, S-GO, and L-GO. Wang et al. (2015a)\nLung fibrosis at 21 days after PA of BSAGP, S-GO, and L-GO. No pro-fibrogenic effects after PA of PF-GP. Strongest response after PA of L-GO.\nS-GO (S: 50e350 nm, T: 1.0 nm, single layer), L-GO (750e1300 nm, T: 1.0 nm, single layer)\nMale BALB/c mice (6) PA (single) 2.5 mg/ kg 72 h [ Total protein and cells, IL-6, CD45þCD54þ cells, and CDllbþ, CD11bþ\nF4/80þ, and CD11bþGr1þ subpopulation of CD45þCD54þ cells in BALF, and serum IL-6 after PA of S- and L-GO. Stronger response after PA of L-GO.\nMa et al. (2015)\nin the pleural space. The authors suggested that the absence of the biological effect of GP in the lungs was not correlated with the degradation and subsequent clearance of the deposited GP.\nMice underwent the intratracheal instillation of GO and were assessed for acute and subchronic pulmonary toxicity (Li et al., 2013). BALF examinations showed that GO caused acute lung cell injury and alveolar permeability to vascular proteins. The lung histopathology revealed that GO induced fibroproliferation and the organization of lung tissue in the acute phase and diffuse pulmonary fibrosis in the subchronic phase. In the lung tissues, GO decreased the activity of antioxidants and reached a minimum at 48 h, suggesting that oxidative stress is associatedwith GO-induced acute lung injury.\nInflammatory changes in BALF and pulmonary fibrosis were observed in mice administered a pharyngeal aspiration of bovine serum albumin-coated GP (BAS-GP), small-sized GO (S-GO), or large-sized GO (L-GO), and the strongest responses were found after the aspiration of L-GO (Wang et al., 2015a). However, no profibrogenic effects were observed after aspiration of PF108dispersed GP (PF-GP). The authors noted that surface reactivity and size have important roles in the induction of pulmonary fibrosis. Stronger inflammatory responses were also reported in the lungs of mice after a single pharyngeal aspiration of larger GO (750e1300 nm) comparedwith smaller GO (50e350 nm) (Ma et al., 2015).\nTo summarize the findings on the pulmonary toxicity of GP and GO in mice and rats after a single bolus pulmonary exposure, GP and GO induced acute inflammatory responses in the lungs. At high doses, GP and GO also induced subacute and subchronic pulmonary inflammation, respectively. GP was suggested to be not fully biopersistent, and clear slowly to the mediastinal lymph nodes. The dispersion of GP might reduce the potential toxicity. Surface reactivity and size play important roles in the induction of pulmonary fibrosis. Aggregated GP and larger sized GO caused stronger inflammatory responses in the lungs. Oxidative stress is suggested to be associated with acute lung injury.\n2.2. Systemic toxicity in mice and rats exposed by intravenous or intraperitoneal injection\nSystemic toxicity of GNMs is presented in Table 3. C57BL/6 mice received a single intravenous injection of GP-2 (2- nm thickness) or GP-5 (5-nm thickness) (Wang et al., 2013a). GP suspensions were dispersed by cup horn sonication. In BALF, GP-2 increased levels of interleukin (IL)-33 and its soluble receptor, sST2, and GP-5 increased levels of IL-33 at 1 day after injection. GP2 also increased BALF levels of IL-5 and -13 in C57BL/6 but not in\nST /- mice at 1 day. GP-2 increased the number of neutrophils at 1 day after injection and GP-5 increased the number of eosinophils and lymphocytes at 7 days in BALF of C57BL/6. No changes in differential cell counts were observed in BALF of ST /- mice. The histological examination of the lung revealed that GP-2 and -5 translocated from the capillaries into the alveolar air spaces in both strains of mice. The authors suggested that inflammatory/Th2 immune responses induced by GP were mediated by the IL-33/ST2 axis.\nExpanded acute toxicity, toxicokinetics, and respiratory/cardiovascular safety pharmacology studies of GP fuctionalized with dextran (DEX-GP), which has the highest level of dispersion achieved for any water-dispersible GP, were performed as a part of the preclinical safety pharmacological evaluation under good laboratory practice (GLP) (Kanakia et al., 2014). DEX-GP was administered to rats by a single intravenous injection. Only at higher doses, death due to pulmonary congestion and histopathological congestion in major vital organs, except for the brain, were observed. The author noted that there were no apparent DEX-GP-related effects on mortality, histopathology, respiratory, or cardiovascular safety parameters, the immune system, or induction of inflammation at doses under 125 mg/kg.\nPristine GP, polyethylene glycol functionalized GP (PEG-GP), or COOH-GP was intravenously injected into mice (Sasidharan et al., 2015). GP and COOH-GP caused acute and subchronic inflammation in the lungs, degenerating changes in the liver, spleen, and kidney, and increased levels of serum biochemical parameters for hepatic and renal injury. However, PEG-GP did not affect histopathology of the major organs or serum biochemical markers even at 90 days after injection. None of the GPs affected histopathology of the brain, heart, or testes.\nDeaths occurred in 4 of 9 mice due to mechanical block of the airways by the GO conglomeration after a single intravenous injection of GO at 0.4, but not 0.1 or 0.25, mg/mouse (Wang et al., 2011). Survivors showed weakness and a decreased body weight. GO caused dose-dependent pulmonary inflammation responses including neutrophil infiltration and foamy macrophage accumulation, epithelioid granulomas, and interstitial inflammation. The early development of lesions was first noted at 7 days, and a diffuse pattern of multi-focal macrophage-containing granulomas and remaining GO in the lungs were observed at 30 days.\nIn mice administered GO by a single intravenous injection, histopathological examinations revealed inflammatory changes in the lungs at 10 mg/kg but no changes in the liver, spleen, or kidney at 1 and 10 mg/kg (Zhang et al., 2011b). In contrast no clear histopathological changes were observed even at 20 mg/kg in organs including the lungs of mice after a single intravenous injection of\nDEX-GO (Zhang et al., 2011a). GO suspended in PBS or PBS containing Tween 80 was administered to mice by a single intravenous injection (Qu et al., 2013a). Although the addition of Tween 80 greatly changed the aggregative behaviors of GO by abolishing its negative charge, neither preparation induced significant histopathological changes in the lungs, liver, kidney, brain, or testes and neither affected hematology.\nGO decreased body weight and increased serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine (CRE) levels 24 h after a single intravenous injection in mice (Li et al., 2014). Thereafter, mice recovered from these adverse effects. Histopathological examinations revealed that GO induced acute inflammatory responses in the lungs and subchronic hepatic and pulmonary fibrosis. PEG coating improved these GO-induced adverse effects. No pathological changes were observed in the spleen or kidney until 3 months in either group.\nMice were administered S- (0.54 mm) or L-GO (2.2 mm) by a single or seven intravenous injections (Liu et al., 2015). Three of the 8 mice died after multiple injections of L-GO. Emaciation, piloerection, and decreased activity were observed in this group. Relative weights of the liver decreased and those of the lungs increased after multiple injections of S-GO and L-GO, respectively. Multiple injections of L-GO increased plasma levels of urea, CRE, and LDH and caused pulmonary inflammation and renal tubular injury. Hepatic inflammatory infiltration, but not lung injury, was observed after multiple injections of S-GO. There was no oxidative stress in the liver, spleen, or lungs because of the lack of changes in GHS or MDA levels in these organs.\nA single intravenous injection of GO functionalized with poly 4- styrenesulfonate (PSS-GO) caused acute hepatic injury, as evidenced by increased levels of serum AST, ALT, and alkaline phosphatase (ALP) in mice (Wen et al., 2015). The injury was reversible. Histopathological lesions in the lungs and liver were moderate at 8\nand 16 mg. The accumulation of GO was observed mainly in the lungs and liver.\nNo inflammatory responses in the peritoneal lavage or granuloma formation in the diaphragms were induced in mice after a single intraperitoneal injection of purified GO which removed byproducts and contaminants (Ali-Boucetta et al., 2013).\nMultiple intraperitoneal injections of GO decreased the Ter199þ population (representing erythroid cells) and increased the percentage of apoptotic Ter119þ cells in the spleen, but not in the bone marrow, of mice (Qu et al., 2013b). GO also impaired red blood cells (RBCs), leading to a decreased number of peripheral RBCs. The authors noted that GO could induce the apoptosis of erythroid cells and possess the potential to disrupt the balance of erythropoiesis.\nMultiple intraperitoneal injections of GO had no acute toxic effects in mice (Kurantowicz et al., 2015) and no acute or subacute toxic effects, except for alterations in oxidative stress parameters in rats (Strojny et al., 2015). In these studies, small dots of GO of around 2 nm in diameter were observed among the mesentery and in the proximity of the spleen serosa.\nInflammatory responses were systematically and locally induced by multiple intraperitoneal injections and a single intravenous injection of S- (50e350 nm) and L- (750e1300 nm) GO in mice (Ma et al., 2015). Stronger inflammatory responses were observed after intraperitoneal and intravenous injections of L-GO, compared with S-GO. The authors reported that L-GO was prone to plasma membrane absorption to activate the toll-like receptors (TLRs) and nuclear factor (NF)-kB pathways, whereas S-GO was mostly taken up by macrophages.\nMice received a single intravenous injection of GO, NH2-GO, poly(acrylamide)-fuctionalized GO (PAM-GO), poly(acrylic acid)functionalized GO (PAA-GO), or PEG-GO (Xu et al., 2016). Modification of GO with NH2, PAM, PAA, PEG reduced the lethality by GO. The gross toxicity of NH2-, PEG-, and PAA-GOs was lower than that\nof GO. GO induced inflammatory changes in the lungs and potential liver damage. The most severe damage was observed after injection of GO and PAM-GO. The least damage in the lungs and liver was observed after injection of PAA-GO, compared with the other GO materials. The authors indicated the important role of chemical modifications on the GO surface in causing toxicity, and PAAmodification represented a safer design feature for GO.\nNo toxicity was observed in mice after a single intravenous injection of PEG-GO (Yang et al., 2011), a single intraperitoneal injection of GO, PEG-nano GO, -rGO, or -nano rGO (Yang et al., 2013), or a single oral administration of PEG-nano GO (Yang et al., 2013). However, multiple intraperitoneal injections of PEG-GO at 20 mg/ kg killed 3 of 12 mice, probably due to the aggregation of PEG-GO and thus a thrombus (Chong et al., 2014).\nRats received a single intravenous injection of rGO at 7 mg/kg (Mendonça et al., 2016). rGO produced minimal toxicity in rats.\nAlthough multiple intravenous and intraperitoneal injections of PEG-GP quantum dots (PEG-GQDs) showed no clear toxicity inmice (Chong et al., 2014), multiple intravenous injections of COOH-GQDs at 10 mg/kg caused moderate histopathological changes in the liver and lungs of rats (Nurunnabi et al., 2013).\nIn summary, the intravenous injection of DEX-GP and GO at high doses caused deaths probably due mechanically to pulmonary congestion. At relatively lower doses, GP induced immune responses and GO induced acute inflammatory responses in the lungs and subchronic hepatic and pulmonary fibrosis. DEX-GP, PEGGPQDs, and COOH-GPQDs did not show apparent toxicity after intravenous or intraperitoneal injection. L-GO was more toxic than small-sized GO. Surfacemodifications attenuated the toxicity of GO.\n2.3. Behavioral toxicity\nBehavioral effects of rGO were determined after repeated oral administration in mice (Zhang et al., 2015) (Table 4). S-rGO (88.0 nm) and L-rGO (472.1 nm) were dispersed in HEPES buffer and treated with ultrasonication for approximately 30 min. Both rGOs transiently decreased locomotor activity in the open-field test and time spent on the rotarod. Neither rGO affected exploratory or anxiety-like behavior or spatial learning and memory. The authors speculated that the reduced movement in the open-field and rotarod tests might be due to the degeneration of general condition of mice caused by the high dose of rGO, but not due to impairment of the central nervous system, because only a small amount of rGO was transiently retained in the brain and no biochemical or morphological changes were induced in the brain.\nA single intravenous injection of rGO induced neither behavioral changes in the functional observation battery test nor morphology of the hippocampus in rats (Mendonça et al., 2016; in Table 3).\n2.4. Reproductive and developmental toxicity\nA few studies using mice have been conducted on the reproductive and developmental toxicity of GO; these were already described in detail in our previous review (Ema et al., 2016b) and also are only briefly summarized in this section (Table 4). No adverse effects of S-GO (55 nm) or L-GO (238 nm)were observed on male reproduction in mice intravenously and intraperitoneally injected (Liang et al., 2015). Although no reproductive or developmental adverse effect was observed after intravenous injection of SrGO (68 nm) or L-rGO (659 nm) before mating or during early gestation, deaths and abortions were observed after injection of SrGO during late gestation, (Xu et al., 2015). Decreased maternal water consumption containing GO during lactation could have reduced milk production and, thus, growth of the offspring (Fu et al., 2015). No histopathological changes in the testes of mice\nwere reported after intravenous injection of GO (Qu et al., 2013a), GP, COOH-GP, or PEG-GP (Sasidharan et al., 2015) (Table 3).\nIn summary, only limited information suggested that intravenous injection of rGO and oral administration of GO potentially induced toxicity.\n2.5. Genotoxicity\nThree reports are available describing genotoxicity studies of GNMs in mammals. After inhalation of GP at 0.12e1.88 mg/m3 for 4 weeks (6 h/day, 5 days/week), comet assay was performed using rat lung tissue at post-exposure days 1 and 28 (Kim et al., 2016, Table 1). Although deposition of GP was observed, the tail moment value did not show any significant changes, indicating no genotoxicity of GP.\nAn in vivo micronucleus assay of GO was performed in mice administered GO by repeated intravenous injection (Liu et al., 2013) (Table 4). In the bone marrow, the frequency of micronuleated polychromatic erythrocytes (MNPCEs) was increased in a dosedependent manner, but the ratio of polychromatic erythrocytes to normochromatic erythrocytes (PCE/NCE) was not changed. GO was suggested to be potentially genotoxic, but not cytotoxic.\nA single intravenous injection of rGO did not affect frequency of micronucleated erythrocytes in the circulating blood of rats (Mendonça et al., 2016; in Table 3).\n2.6. Ocular toxicity\nThree reports are available on ocular toxicity of GP and GO (Table 4). In rabbits, no significant adverse effects on the ocular system were noted on a single intravitreal injection of hydroxyl (OH-) GP (Lin et al., 2015) or GO (Yan et al., 2012).\nAn acute eye irritation test of GO was performed using rabbits according to the OECD guideline (Wu et al., 2016). GO did not cause corneal opacity, conjunctival redness, abnormality of the iris, chemosis, or impairment of the corneal epithelium in rabbits, indicating no acute eye irritation of GO. In rats, 5-day repeated administration of GO induced reversible mild corneal opacity, conjunctival redness, and corneal epithelium damage at 100 and 200 ng. The antioxidant GSH inhibited the eye toxicity of GO.\n2.7. Biodistribution\nBiodistribution studies of GNMs have been reported (Table 5). 14C-labeled GP was given to mice by a single intratracheal instillation or oral gavage (Mao et al., 2016). On 1 day after instillation, the radioactivity was detected largely in the lung and slightly in the large and small intestines, stomach, and feces. On day 7, the radioactivity increased in the feces and was detectable in the liver and spleen. On day 28, 47% of the exposure dose (ED) remained in the lung. Transmission electron microscope (TEM) analysis revealed the GP in the cytoplasm of alveolar macrophages. The authors suggest that intratracheally instilled GP passes through the air-blood barrier in to the blood and is translocated to other organs. After oral gavage of GP, it was not absorbed from the gastrointestinal tract and excreted through the feces.\nIn mice that received a single intravenous injection of DEX-GP, more DEX-GP remained in the heart and liver on day 1 and in the heart on day 30 (Kanakia et al., 2014). The percentage of injected DEX-GP remaining in the major organs was ~0.5e4% on day 1, with maximum organ accumulation at 50 mg/kg and the least accumulationwith 500 mg/kg. DEX-GP was removed from these organs until day 30. DEX-GP was mainly excreted within 24 h through the feces.\nPristine GP, COOH-GP, and PEG-GP were intravenously injected\ninto mice (Sasidharan et al., 2015). GP and COOH-GP formed large aggregates and accumulated within the organs. Raman spectral mapping analysis revealed that, even at 3 months, GP was retained in the lungs, liver, and spleen and COOH-GP was retained in the lungs, liver, spleen, and kidney, but PEG-GP was only detected in trace concentrations in the liver and spleen, with no accumulation in the brain, heart, or testes. Significant alteration was observed in the Raman signature of COOH-GP and PEG-GP. The authors suggested that COOH-GP damaged organs because of its slow degradation and that PEG-GP is cleared or biodegraded without serious damage.\nAfter the intratracheal instillation of 125I-labeled GO in mice, the radioactivity in the lung reached a maximum at 10 min and then gradually decreased (Li et al., 2013). A low level was observed in other organs and the radioactivity increased over the first several hours in the organs. Relatively higher levels were observed in the urine within 6 h. These findings suggest that GO passes through the air-blood barrier into blood and GO is delivered to the organs and eliminated by a renal route. The deposition of GO in the lung was gradually decreased from 24 h to 3 months after instillation, suggesting that GO is slowly cleared from the lung. Alveolar macrophages laden with GO accumulated in the bronchial lumen at 3 months.\nAfter a single intravenous injection of GO in mice, GO was located primarily in the lungs, liver, and spleen, but no GO was observed in the brain (Wang et al., 2011). A low level of GO in the\nkidney suggests no renal clearance. TEM images showed that GO still remained in the lungs after 1 month.\nIn mice administered 188Re-labeled GO by a single intravenous injection, radioactivity was distributed throughout most of the organs within 48 h, and primarily accumulated in the lungs, liver, and spleen, and to a much lesser extent in the heart, kidney, bone, stomach, and brain at 48 h (Zhang et al., 2011b). In mice administered 125I-labeled DEX-GO by a single intravenous injection, the radioactivity was distributed in several organs including the liver, spleen, stomach, lung, kidney, and intestine at 4 h, and showed dominant reticuloendothelial system (RES) uptake in the liver and spleen at later time-points (days 3 and 7) with negligible lung accumulation (Zhang et al., 2011a).\nMice received a single intravenous injection of 125I-labeled S-GO (100e500 nm) or L-GO (1e5 mm) (Liu et al., 2012). S-GO predominantly accumulated in the liver, with small amounts in the lungs and spleen, and a very small amount in other organs. The uptake reached amaximum at 5min postexposure, and 25.3 and 4.9% of ED were found in the liver and lungs, respectively. At 180 min, 11% and less than 1% of ED remained in the liver and lungs, respectively. In the lungs, L-GO mainly accumulated and 26.8% of ED distributed at 2 min. Only small amounts distributed in other organs (e.g., less than 3% in the liver). At 180 min, 19.1% of ED remained in the lungs. TEM analysis revealed that nanosized particles and aggregates were distinguished intracellularly in the liver after the injection of S-GO and particles larger than 1 mm were found in the cell gap in\nTable 5 (continued )\nTest materials Dosing solutions Animals (No. of animals/ group)\nExposure Autopsy after exposure Findings Reference Routes Doses\nthyroid (~4%), heart and skin (~3%), muscle (~1%). At day 3, very low radioactivity in these organs, except spleen (~7.5%) and liver (~6%). See toxic effect in Table 3\nGO (D: 450 nm, T: 0.94 nm, PEG-nano GO (D: 25 nm, T: 1.22 nm),\nPEG-rGO (D: 50 nm, 4.43 nm), PEG-nano rGO (D: 27 nm, T: 5.66 nm) 125I-labeled PEGnano GO, 125I-labeled PEGrGO, 125I-labeled PEGnano rGO Female BALB/ c mice (5) IP (single) 4 mg/kg (20 mCi) 1, 7 days Radioactivity at day 1, %ED/g: liver (~9e11%) and spleen (~6e9%) at day 1, and liver (~8e17%) and spleen (~9e23%) at day 7. Almost twice the radioactivity of PEG-rGP compared with PEG-nano GO and nano rGO at day 7. Yang et al. (2013) See toxic effect in Table 3\nPO (single)\n4 h, 1, 7 days High radioactivity in stomach (10e15% ED/g) and intestine (3e5% ED/g) at 4 h. Low radioactivity in all organs at day 1. Undetectable radioactivity at day 7.\nGO (S: ~10e800 nm, T: ~1 nm, ZP: 32.1 mV), PEG-GO (ZP: 25.3 mV)\n125I-labeled GO, 125I-labeled PEGGO Male Kunming mice (5)\nIV (single)\n10 min-6 h At 10 min, 55.9% of injected 125I-GO in liver and 10% in lung and 2.2% in spleen, and less than 2% in other organs. Lower radioactivity of PEG-GO in these organs than GO. Li et al. (2014) See toxic effect in Table 3\nS-rGO (S: 88.0 nm, sheet-like), L-rGO (S: 472.1 nm, sheet-like) 125I-labeled S-rGO, 125I-labeled L-rGO in HEPES buffer Male C57BL/ 6 mice (4) PO (5 days) 60 mg/ kg/day 1, 15, 60 days Radioactivity at day 1, %ED/g: kidney (~0.7e0.9%), stomach (~0.2%), liver, lung, and blood (~0.1%). Negligible radioactivity in liver, kidney, and brain at day 60. Very low radioactivity in brain at 1 day and near zero at days 15 and 60. Same distribution and rate of metabolism of S- and L-rGO. Zhang et al. (2015) See toxic effect in Table 4 COOH-GQDs (S: 3e6 nm) Photoluminescent COOH-QODs\nTumorbearing female SKHI nude mice (3) IV (single) 5, 10 mg/ kg 2-24 h Accumulation mainly in tumor site, liver, kidney, lung, and spleen. (analyzed by noninvasive imaging) Nurunnabi et al. (2013) See toxic effect in Table 3\nthe lungs, rather than inside the cells. The authors noted that GO was quickly cleared from the blood and accumulated predominantly in the liver and lungs, and the GO uptake in the lungs increased with increasing dose and size.\nRepeated doses of 125I-labeled S-GO (55 nm) were intravenously or intraperitoneally injected into male mice (Liang et al., 2015). Radioactivity distributed mainly in the lung, spleen, and liver after intravenous injection and in liver and spleen after intraperitoneal injection. Negligible radioactivity was found in the testis and epididymis. The highest radioactivity was observed in the lungs and liver after intravenous and intraperitoneal injection, respectively. Much higher radioactivity was observed after intravenous than intraperitoneal injection.\n125I-labeled S-rGO (68 nm) distributed mainly in the maternal lung, spleen, and kidney and negligibly in the placenta and fetuses of mice intravenously injected with a single dose on around gestational day (GD) 19 (Xu et al., 2015). The findings suggested that S-rGO did not transfer from dams to fetuses during late gestation.\nDyeCy7-PSS-GO distributed mainly in the liver, with low levels in the bladder within 24 h and, thereafter, gradually accumulated in the liver, lungs, spleen, and bladder in mice after a single intravenous injection (Wen et al., 2015). The authors suggested the renal clearance of PSS-GO.\nThe addition of Tween 80 markedly changed the aggregative behavior of GO by abolishing its negative charge, and decreased GO accumulation in the lungs (Qu et al., 2013a; in Table 3). A higher accumulation of GO in PBS containing Tween 80 was observed in the liver than that of GO in PBS after a single intravenous injection into mice. In the lungs, GO agglomerates were located within macrophages. In the liver, most GO agglomerates were located within Kuppfer cells (macrophages) and no GO was found within hepatocytes. GO agglomerates were not found in the kidney, brain, or testes. The authors noted that surfactant Tween 80 markedly changed the pattern of the biodistribution of GOwith decreased GO\naggregation in the lungs and an increased amount in the liver. In mice that received a single intravenous injection of 125Ilabeled PEG-GO, radioactivity was detected at 1 h in many organs including the spleen, liver, stomach, kidney, lung, heart, intestine, bone, thyroid, skin, and muscle, but mainly accumulated in the RES such as the spleen and liver (Yang et al., 2011). The bone uptake of PEG-GOwas suggested to be due to themacrophage uptake of PEGGO in the bone marrow, and the kidney and intestine uptake of PEG-GO was suggested to be associated with renal and fecal excretion, respectively. At 3 days, radioactivity in these organs, except for the spleen and liver, became very low. The findings suggest the gradual clearance of PEG-GO from mice via both renal and fecal clearance. It has also been reported that administered PEG-GO accumulated in the RES of both dead and surviving mice (Chong et al., 2014; in Table 3).\nBiodistributions of PEG-GO derivatives were determined using 125I-labeled PEG-nano GO, rGO, and nano rGO after intraperitoneal injection and oral administration (Yang et al., 2013). Three types of PEG-GO derivatives highly accumulated in the liver and spleen, and larger-sized PEG-rGO showed nearly 2-fold higher uptake in the liver and spleen compared with smaller-sized PEG-nano GO and nano rGO at 7 days after intraperitoneal injection. After the oral administration, the three types of PEG-GO derivatives are suggested to be in a form difficult to absorb form the digestive tract and were almost totally excreted 7 days after administration.\nThe effect of PEG-coating on the biodistribution of GO was investigated using 125I-labeled GO and 125I-labeled PEG-GO in mice intravenously injected (Li et al., 2014). Data indicated that GO mainly accumulated in the liver, lung, and spleen and PEG coating reduced the retention of GO in these organs and promoted its clearance from these organs.\nAfter multiple oral administrations of 125I-labeled S- (88.0 nm) and L-rGO (472.1 nm) in mice, labeled rGO was transferred into the blood and distributed throughout the whole body (Zhang et al.,\n2015). The distribution and rate of metabolism of S- and L-rGOwere the same. rGO mainly distributed in the kidney and then the stomach, liver, and lungs. Although a low level of rGO distributed in the brain on 1 day after injection, only a negligible amount of rGO was detected at 15 and 60 days.\nOptical imaging and biodistribution studies were conducted in mice intravenously injected with photoluminescent COOH-GQDs (Nurunnabi et al., 2013). COOH-GQDs mainly accumulated in the tumor site, liver, kidney, lungs, and spleen.\nTo summarize the findings on the biodistribution of GNMs, intratracheally instilled GP passed through the air-blood barrier into the blood and was delivered to the organs, and oral GP was difficult to absorb from the gastrointestinal tract. Intravenous DEXGP distributed mainly in the heart and liver and was removed from the organs, except for the heart, until day 30. Intravenous GO distributed in the lungs, liver, and spleen, and to a much lesser extent in the brain, heart, bone, and testes. Smaller GO mainly accumulated in the liver and larger GO mainly accumulated in the lungs. Oral rGO was transferred into the blood and distributed throughout the whole body, but intravenous S-rGO did not transfer from dams to fetuses during late gestation. Surfactant markedly changed the pattern of the biodistribution of GO, and surface modification of GP and GO reduced the retention in the organs and promoted clearance. COOH-GQDsmainly accumulated in the tumor site, liver, kidney, lungs, and spleen.\n3. Discussion and conclusions\n3.1. Evaluation of published literature\nWe thoroughly reviewed the toxicology studies of GNMs, which comprise GP, functionalized GP, GO, functionalized GO, rGO, functionalized rGO, and functionalized GQD, administered via various routes in mice, rats, and rabbits. Various types of toxicity were induced (Fig. 1). The majority of studies on the systemic toxicity, biocompatibility, and biodistribution of GNMs were performed via injection, specifically intravenous injection. The injection route is\nsuggested to be relevant for human exposure because GNMs are expected to be used in biomedical applications. Furthermore, studies using intravenous injection are expected to provide information on the potential effects of GNMs once they have entered the bloodstream. In four reports, studies were conducted using oral exposure. Oral exposure is considered to be the main route of consumer or environmental exposure to GNMs and may occur through the ingestion of contaminated water and food once GNMs are released into the environment and transported into the air, soil, water, and sediments. A number of studies were conducted to evaluate the pulmonary toxicity of GNMs using airway exposure, such as inhalation, intratracheal instillation, pharyngeal aspiration, and intrapleural injection. Airway exposure is the most relevant for GNMs, as inhalation represents the main route of exposure in an occupational setting. Although inhalation is the gold standard for determining the potential toxicity of inhalants (Jacobsen et al., 2009; Baisch et al., 2014), only four papers are available on noseonly inhalation toxicity studies of GNMs. The outcomes of inhalation exposure were very similar to those seen after bolus administration, such as intratracheal instillation and pharyngeal aspiration, leading to pulmonary toxicity (Costa et al., 2006; Shvedova et al., 2008; Castranova et al., 2013). Shvedova et al. (2008, 2014) reported that inhalation exposure to single-walled carbon nanotubes (SWCNTs) caused greater inflammatory responses in the lungs than bolus pharyngeal aspiration. In contrast, bolus intratracheal instillation induced higher inflammatory responses than inhalation on single and repeated exposures to titanium dioxide when deposited doses were constant (Baisch et al., 2014). In this review paper, we showed that repeated inhalation exposure to GP and GO induced only minimal pulmonary toxicity/ inflammation shortly after exposure, and that bolus exposure to GP and GO induced relatively severe pulmonary inflammation. These findings suggest that bolus exposure to GNMs results in stronger pulmonary inflammation than inhalation exposure. However, further studies are needed to draw a definitive conclusion, because Krug (2014) noted that data obtained from a bolus exposure study must be carefully evaluated because the results can be affected by\nraphene; GO, graphene oxide; rGO, reduced graphene oxide; GQDs, graphene quantum\nthe effects of agglomeration and excessive high local concentrations.\nRecovery from acute inflammation was observed after intratracheal instillation of GP at 5e50 mg/mouse (Duch et al., 2011; Mao et al., 2016), pharyngeal aspiration of GP at 50 mg/mouse (Schinwald et al., 2012, 2014), and intrapleural injection of GP at 5 mg/mouse (Schinwald et al., 2012). However, no recovery was observed after intratracheal instillation of GO at 50 mg/mouse (Duch et al., 2011) or pharyngeal aspiration of GO at 50 mg/mouse (Wang et al., 2015a). These findings suggest that GP shows less pulmonary toxicity than GO. However, GO is considered more biocompatible than GP due to its greater solubility and dispersibility, which results in it being less toxic to cells (Nezakati et al., 2014). Further studies are needed to clarify this issue because of limited data available on the pulmonary toxicity of GP and GO.\nAirway exposure to SWCNTs caused clear cardiovascular and systemic toxicity (Ema et al., 2016a). However, airway exposure to GNMs did not induce clear systemic toxicity even though labeled GNMs were detected in the major organs after intratracheal instillation of GP (Mao et al., 2016) and GO (Li et al., 2013). These findings suggest that GP and GO can translocate from the lungs to the systemic circulation by crossing the alveolar-capillary barrier, and that GP and GO are less toxic than SWCNTs.\nIntravenous injection of GP (Wang et al., 2013a), DEX-GP (Kanakia et al., 2014), COOH-GP (Sasidharan et al., 2015), GO (Wang et al., 2011; Zhang et al., 2011b; Liu et al., 2015; Xu et al., 2016), and PSS-GO (Wen et al., 2015) predominantly caused pulmonary inflammation. The intraperitoneal injection of GO (Qu et al., 2013b; Strojny et al., 2015) and PEG-GO (Chong et al., 2014) mainly induced liver and spleen toxicity. These phenomena may be explained by the biodistribution of GNMs. GNMs largely accumulated in the lungs after intravenous injection of GP and COOH-GP (Sasidharan et al., 2015), and GO (Wang et al., 2011; Zhang et al., 2011b; Liu et al., 2012). Higher accumulations of GO (Liang et al., 2015) and PEG-GO and rGO (Yang et al., 2013) were observed in the spleen and liver after intraperitoneal injection. Overall, GNMs seem to be predominantly accumulated in the RES-enriched liver, lungs, and spleen.\nOne study revealed that oral rGO was absorbed from the gastrointestinal tract, distributed in many organs, and altered mouse behavior (Zhang et al., 2015). Another two studies on oral administration showed that GP (Mao et al., 2016), GO, PEG-GO, and PEG-rGO (Yang et al., 2013) are in a form that is difficult to absorb form the gastrointestinal tract. These three GO derivatives did not show toxicological effects (Yang et al., 2013). Further studies on absorption from the gastrointestinal tract and biodistribution of orally administered GNMs are required to elucidate the toxicity, because the absorption, translocation, and biodistribution of GNMs are critical factors in evaluating their potential toxicity.\nOnly limited information is available on the behavioral, reproductive, and developmental toxicity and genotoxicity of GNMs. The reported findings indicate that some GNMs possess potential adverse effects, but overall, data are still very limited. No testicular toxicity was reported after the intravenous injection of GO (Qu et al., 2013a; Liang et al., 2015), GP, COOH-GP, or PEG-GP (Sasidharan et al., 2015) or after intraperitoneal injection of GO (Liang et al., 2015). No clear developmental toxicity of oral GO (Fu et al., 2015) or intravenous rGO (Xu et al., 2015) or behavioral toxicity of oral rGO (Zhang et al., 2015) was also reported. These experimental results may be supported by the following findings on the biodistribution of GNMs. No accumulation of GP, COOH-GP, or PEG-GP (Sasidharan et al., 2015) and negligible accumulation of GO (Liang et al., 2015) in the testes were reported. Negligible transplacental transfer of rGO (Xu et al., 2015) and very low accumulations of GO (Zhang et al., 2011b) and rGO (Zhang et al., 2015) in\nthe brain were also reported. GNMs seem to be hard to translocate through the biological barrier. Studies on toxicokinetics of GNMs are urgent issues, because the placental, blood-testes, and bloodbrain barriers are critical in developmental, testicular, and behavioral toxicity. Three reports are available describing genotoxicity studies of GNMs in rodents and GO was suggested to be genotoxic in mice. Table 6 summarizes studies on in vitro genotoxicity of GNMs. Positive results have been reported in in vitro genotoxicity studies of GP (Chatterjee et al., 2016), GO (Qiao et al., 2013; Wang et al., 2013b; Ivask et al., 2015; Hashemi et al., 2016), rGO (Akhavan et al., 2012), and GQDs (Wang et al., 2015b) (Table 6). If these GNMs reach target cells in the body after exposure of animals to GNMs, there is the potential for induction of genotoxicity in animals. To further elucidate the genotoxicity of GNMs, further genotoxicity studies are needed and absorption and distribution of GNMs should be investigated using the same regimen that revealed in vivo genotoxicity.\n3.2. Toxicity mechanisms\nThe main mechanism for toxicity of NMs is currently proposed to be generation of ROS resulting in oxidative stress, which stimulate inflammatory responses (Stone et al., 2009; Møller et al., 2010). This proposal is thought to be true for GNMs. The generation of intracellular ROS in target cells is a potentially initial mechanism for toxicity of GNMs (Jastrzębska et al., 2012; Lalwani et al., 2016). The accumulation of intracellular ROS is the main characteristic of oxidative stress, so the detection of ROS generation reflects the intracellular oxidative stress status (Li et al., 2012). GP (Zhang et al., 2010; Duch et al., 2011; Li et al., 2012) and GO (Singh et al., 2011, 2012) have a potential effect on ROS generation in the presence of cells. Meanwhile, Lee et al. (2016) reported increased ROS generation from GP and derivatives in a cell-free assay system. The measurement of ROS generation in a cell-free environment is not a measure of oxidative stress, because oxidative stress can only occur in biological cells or organisms and is defined as the result of an imbalance between prooxidants (e.g., ROS) and antioxidant defense mechanisms of the body (Stone et al., 2009). The airway and injection route of exposure to GNMs clearly showed inflammatory responses. The intratracheal instillation of GO decreased activity of antioxidants, SOD and GSH-PX, suggesting that oxidative stress is associated with GO-induced acute lung injury in mice (Li et al., 2013). GSH inhibited eye toxicity induced by GO in rats (Wu et al., 2016). The oral administration of rGO slightly decreased serum SOD levels in mice (Zhang et al., 2015). The intravenous injection of rGO also decreased serum levels of SOD in rats (Mendonça et al., 2016). These findings suggest that GNMs can induce oxidative stress and resulted in inflammation, which are causative factors of GNM toxicity.\nHowever, oxidative stress is not dominant toxicological mechanism of intravenous GNMs, because GO did not change GSH or MDA levels in the liver, spleen, or lungs (Liu et al., 2015) and rGO increased levels of GSH and decreased levels of MDA in the rat liver after intraperitoneal injection, suggesting the lack of oxidative stress in the liver (Strojny et al., 2015). Furthermore, direct interaction between the cell membrane and GO was proposed as the toxicological mechanism of GO because the cytotoxicity of GO was markedly mitigated when it was incubated with serum due to the high protein absorption ability of GO (Hu et al., 2011). GPwith sharp edges can induce direct physical damage, leading to membrane destabilization and loss of cell integrity (Lalwani et al., 2016). Size dimensions of GP may affect the different receptors responsible for the energy-dependent mechanisms of cell penetration (Bianco, 2013). The markedly hydrophobic surface of some GNMs may lead to significant interactions with membrane lipids to direct\nphysical toxicity or the absorption of biological molecules, leading to indirect toxicity (Sanchez et al., 2012; Bianco, 2013). Further studies are required to better understand the mechanism of GNM toxicity.\n3.3. Effect of physico-chemical properties on toxicity\nThe biological effects of GNMs vary with their physico-chemical properties, including morphology, surface chemistry/coating, and purity. The shape and size can influence their cellular uptake characteristics, functional groups can alter their interactions with proteins, biomolecules, and micronutrients, the dispersed status of the test suspension can influence toxicity, and surface coating with biocompatible moieties can mitigate toxicity (Lalwani et al., 2016).\nFibers, which have a high aspect ratio and long, thin, rigid, and biopersistent properties, may induce pulmonary responses similar to asbestos (Poland et al., 2008; Braakhuis et al., 2014). Long fibers are more slowly cleared as they cannot be easily enclosed by macrophages, leading to frustrated phagocytosis, and this concept has been accepted as a keymechanism for the toxicity of long fibers (Donaldson et al., 2010; Schinwald et al., 2012). This structureactivity relationship seen with the long fiber-like structure does not take sheet/platelet shape particles into account and, therefore, has to be reconsidered in the light of new materials (Schinwald et al., 2012). Clear signs of frustrated phagocytosis were observed in pleural macrophages after intrapleural injection of GP\n(Schinwald et al., 2012). This phenomenon disappeared up to 7 days after injection, and GP was suggested to be degraded into small fragments which could be cleared by macrophages. The biodegradation of tissue-bound PEG-GP and COOH-GP was also suggested (Sasidharan et al., 2015). Seabra et al. (2014) noted that GP nanostructures are not fiber-shaped and theoretically offer significant advantages in terms of safety over inhomogeneous dispersions of carbon nanotubes. To clarify this point of view, further studies are required to evaluate the biopersistence and shape of GNMs and their impact on pathogenicity.\nThe size of GNMs may influence their toxicity. Three reports showed that L-GO caused stronger toxicity/inflammation than SGO. After pharyngeal aspiration, L-GO induced stronger pulmonary inflammatory responses than S-GO (Wang et al., 2015a). Regardless of exposure routes, L-GO induced stronger inflammatory responses than S-GO (Ma et al., 2015). After multiple intravenous injections, more severe toxicity was caused by L-GO than S-GO, and hepatic inflammatory infiltration was observed after multiple injections of S-GO (Liu et al., 2015). These findings are in close agreement with the following findings of studies on biodistribution. The liver is the primary organ responsible for the accumulation of S-GO, and the lung is the primary organ responsible for the accumulation of L-GO (Liu et al., 2012, 2015). Furthermore, it is suggested that the clearance of GO from the kidney is size-dependent and GO of small sizes is quickly eliminated via the renal route (Zhang et al., 2011b; Li et al., 2014).\nMost GNMs tend to aggregate in physiological solutions due to electrostatic charges and nonspecific binding to protein, and therefore, the development of functionalized GNMs has improved their solubility and biocompatibility, and reduced toxicity (Guo and Mei, 2014). In this review, we showed that the fuctionalization of GNMs modified their toxicity. GP and COOH-GP, but not PEG-GP, caused histopathological changes in the major organs (Sasidharan et al., 2015). PEG-GO lessened GO-induced toxic effects (Li et al., 2014). There is a marked difference in the biodistribution and lung toxicity between as-prepared GO (Zhang et al., 2011b) and DEX-GO (Zhang et al., 2011a). GO showed marked uptake and retention in the lungs with histopathological changes, and the negligible accumulation of DEX-GO in the lungs with no histopathological changes was observed. The dispersant also affects the toxicity of GNMs. The aspiration of GP dispersed in PF-108 produced no fibrosis in the lungs (Wang et al., 2015a). Surfactant Tween 80 markedly changed the pattern of biodistribution of GO (Qu et al., 2013a). Furthermore, the dispersion of GP can reduce the potential toxicity. The intratracheal instillation of dispersed GP induced weaker pulmonary inflammation than that induced by aggregated GP (Duch et al., 2011). Thus, it is suggested that surfacefunctionalization and dispersant improved water dispersity and stability and induced lower-level toxicity of GNMs.\nRegarding the pulmonary toxicity, the dispersion status of SWCNTs has also been shown to influence the deposition and biological effect (Mercer et al., 2008; Shvedova et al., 2014). Contrary to the GNM-induced pulmonary toxicity, well-dispersed SWCNTs induced greater toxicity. The pharyngeal aspiration of well-dispersed SWCNTs induced greater fibrotic potency compared with a less dispersed suspension (Mercer et al., 2008). Dispersed SWCNTs can be deposited in the distal alveoli, rapidly migrate and be incorporated into the alveolar walls, and induce more potent inflammatogenic and interstitial fibrotic reactions in the absence of granuloma formation (Mercer et al., 2008; Shvedova et al., 2014). This discrepancymay be associated with the differences in physicochemical properties including shape and biopersistence between GNMs and SWCNTs.\n3.4. Conclusions and perspectives\nThe available data suggests that pristine and functionalized GNMs exhibit potential pulmonary, systemic, behavioral, reproductive, and developmental toxicity and genotoxicity in laboratory mammals. However, the toxicological information is still very limited, especially when taking into account the many different types of GNMs and their potential modifications. The data suggest that the size, shapes, surface properties and chemistry, concentration, agglomeration, dose, and preparation of GNMs are all determinants of the biological activity that may lead to toxicity. There are indications that oxidative stress and inflammation may be involved in the toxicity of GNMs.\nThere is no evidence regarding nanospecific hazards and mechanisms of action, no step change in hazard, no threshold for the onset of a novel nanospecific hazard, and no novel pathogenic pathway (Donaldson and Poland, 2013; Gebel et al., 2014). There is no evidence so far that fundamentally different biokinetics of NMs would trigger toxicity (Gebel et al., 2014). At present, GNM-specific toxicological outcomes have not been reported. However, there are multiple GP forms, and the different types possess unique physiological properties and, therefore, are expected to exert different toxicological effects. Khan and Shanker (2015) noted that current toxicity testing protocols may be applied to identify the harmful effects of NMs but research into newmethods is required to address the special properties of NMs. Although protocols for traditional toxicological studies are useful to evaluate the toxicity of GNMs,\ntoxicological studies according to the traditional protocol should be performed with particular attention to the concept that the toxicity of GNMs varies with their physico-chemical properties. It is very important to provide data on characterization of GNMs used in toxicological studies because lateral size is a key variable in cell uptake, layer number affects deposition and surface area, and surface chemistry affects absorption and dispersibility (Sanchez et al., 2012). However, many studies cited in this review did not provide information on physico-chemical properties of GNMs in dosing solutions at the time of administration. This information should be provided because the toxicity of GNMs varies with their physicochemical properties, especially dispersion state and sizes of the aggregates.\nThis review showed that many acute toxicity studies have been conducted, but no long-term toxicity studies has been performed. Lung fibrosis was induced by airway exposure to GP (Duch et al., 2011; Wang et al., 2015a; Lee et al., 2016) and GO (Wang et al., 2015a). Inflammation and the resulting fibrosis have been considered as significant risk factors in pulmonary carcinogenesis (Hubbard et al., 2000; Shvedova et al., 2008). Therefore, long-term toxicity studies of GNMs are needed to elucidate their toxicity. In addition, studies on dermal, ocular, reproductive, and developmental toxicity, geno- and immuno-toxicity, and long-term toxicity are highly warranted. To clarify the toxicity of GNMs, studies should be conducted using different types of well-characterized GNMs, standard protocols, and the relevant route and doses of human exposure. Grouping of ENMs and read-across are also needed to fill data gaps, predict the toxicity, and for risk assessment of ENMs including GNMs. The grouping of ENMs should not rely on intrinsic material properties alone and should address all relevant aspects of ENM life cycle and biological pathways, i.e., biopersistence, uptake and biodistribution, cellular and apical toxic effects (Arts et al., 2016). Furthermore, Gebel et al. (2014) noted that most of the reported toxicity due to ENMs can be assigned to one of three categories: chemically mediated toxicity; toxicity caused by fibrous ENMs; and toxicity through granular biodurable ENMs. These approaches can be utilized to facilitate hazard assessment of ENMs.\nConflict of interest\nThe authors declare no conflicts of interest.\nAcknowledgements\nThis study was based on the results obtained from a project entitled: “Innovative Carbon Nanotubes Composite Materials Project Toward Achieving a Low-Carbon Society (P10024)”, which was commissioned by the New Energy and Industrial Technology Development Organization (NEDO) in Japan.\nTransparency document\nTransparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2017.01.011.\nReferences\nAkhavan, O., Ghaderi, E., Akhavan, A., 2012. Size-dependent genotoxicity of graphene nanopalatelets in human stem cells. Biomaterials 33, 8017e8025. Ali-Boucetta, H., Bitounis, D., Raveendran-Nair, R., Servant, A., Van den Bossche, J., Kostarelos, K., 2013. Purified graphene oxide dispersions lack in vitro cytotoxicity and in vivo pathogenicity. Adv. Healthc. Mater 2, 433e442. Arts, J.H.E., Irfan, M.A., Keene, A.M., Kreiling, R., Lyon, D., Maier, M., Michel, K., Neubauer, N., Petry, T., Sauer, U.G., Warheit, D., Wiench, K., Wohlleben, W., Landsiedel, R., 2016. Case studies putting the decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping) into practice. Regul. Toxicol. Pharmacol. 76, 234e261.\nBaisch, B., Corson, N.M., Wade-Mercer, P., Gelein, R., Kennell, A., Oberdr€oster, G., Elder, A., 2014. Equivalent titanium dioxide nanoparticle deposition by intratracheal instillation and whole body inhalation: the effect of dose rate on acute respiratory tract inflammation. Part. Fibre Toxicol. 11, 5. http://dx.doi.org/ 10.1186/1743-8977-11-5. Bengtson, S., Kling, K., Madsen, A.M., Noergaard, A.W., Jacobsen, N.R., Clausen, P.A., Alonsa, B., Pesquera, A., Zurutuza, A., Ramos, R., Okuno, H., Dijon, J., Wallin, H., Vogel, U., 2016. No cytotoxicity or genotoxicity of graphene and graphene oxide in murine lung epithelial FE1 cells in vitro. Environ. Mol. Mutagen 57, 469e482. Bianco, A., 2013. Graphene: safe or toxic? The two faces of the medal. Angew. Chem. Int. Ed. 52, 4986e4997. Braakhuis, H.M., Park, M.V.D.Z., Gosens, I., De Jong, W., Cassee, F., 2014. Physicochemical characteristics of nanomaterials that affect pulmonary inflammation. Part. Fibre Toxicol. 11, 18. http://dx.doi.org/10.1186/1743-8977-11-18. Castranova, V., Schulte, P.A., Zumwalde, R.D., 2013. Occupational nanosafety considerations for carbon nanotubes and carbon nanofibers. Acc. Chem. Res. 46, 642e649. Chatterjee, N., Yang, J.S., Choi, J., 2016. Differential genotoxic and epigenotoxic effects of graphene family nanomaterials (GFNs) in human bronchial epithelial cells. Mutat. Res. Genet. Toxicol. Environ. Mutagen 798e799, 1e10. Chong, Y., Ma, Y., Shen, H., Tu, X., Zhou, X., Xu, J., Dai, J., Fan, S., Zhang, Z., 2014. The in vitro and in vivo toxicity of graphene quantum dots. Biomaterials 35, 5041e5048. Costa, D.L., Lehmann, J.R., Winsett, D., Richards, J., Ledbetter, A.D., Dreher, K.L., 2006. Comparative pulmonary toxicological assessment of oil combustion particles following inhalation or instillation exposure. Toxicol. Sci. 91, 237e246. Donaldson, K., Poland, C.A., 2013. Nanotoxicity: challenging the myth of nanospecific toxicity. Curr. Opin. Biotechnol. 24, 724e734. Donaldson, K., Murphy, F.A., Duffin, R., Poland, C., 2010. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of lung fibre retention in the parietal pleura, inflammation and mesothelioma. Part. Fibre Toxicol. 7, 5. http://dx.doi.org/10.1186/1743-8977-7-5. Duch, M.C., Budinger, G.R.S., Liang, Y.T., Soberanes, S., Urich, D., Chiarella, S.E., Campochiaro, L.A., Gonzalez, A., Chandel, N.S., Hersam, M.C., Mutlu, G.M., 2011. Minimizing oxidation and stable nanoscale dispersion improves the biocompatibility of graphene in the lung. Nano Lett. 11, 5201e5207. Ema, M., Gamo, M., Honda, K., 2016a. A review of toxicity studies of single-walled carbon nanotubes in laboratory animals. Regul. Toxicol. Pharmacol. 74, 42e63. Ema, M., Hougaard, K.S., Kishimoto, A., Honda, K., 2016b. Reproductive and developmental toxicity of carbon-based nanomaterials: a literature review. Nanotoxicology 9, 391e412. Fu, C., Liu, T., Li, L., Liu, H., Liang, Q., Meng, X., 2015. Effects of graphene oxide on the development of offspring mice in lactation period. Biomaterials 40, 23e31. Gebel, T., Foth, H., Damm, G., Freyberger, A., Kramer, P.J., Lilienblum, W., R€ohl, C., Schupp, T., Weiss, C., Wollin, K.M., Hengstler, J.G., 2014. Manufactured nanomaterials: categorization and approaches to hazard assessment. Arch. Toxicol. 88, 2191e2211. Guo, X., Mei, N., 2014. Assessment of the toxic potential of graphene family nanomaterials. J. Food Drug Anal. 22, 105e115. Han, S.G., Kim, J.K., Shin, J.H., Hwang, J.H., Lee, J.S., Kim, T.G., Lee, J.H., Lee, G.H., Kim, K.S., Lee, H.S., Song, N.W., Ahm, K., Yu, I.J., 2015. Pulmonary responses of Sprague-Dawley rats in single inhalation exposure to graphene oxide nanomaterials. Biomed. Res. Int. Article ID 376756 http://dx.doi.org/10.1155/2015/ 376756. Hashemi, E., Akhavan, O., Shamsara, M., Daliri, M., Dashtizad, M., Farmany, A., 2016. Synthesis and cyto-genotoxicity evaluation of graphene on mice spermatogonia stem cells. Colloids Surf. B Biointerfaces 146, 770e776. Hu, W., Peng, C., Lv, M., Li, X., Zhang, Y., Chen, N., Fan, C., Huang, Q., 2011. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano 5, 3693e3700. Hubbard, R., Venn, A., Lewis, S., Britton, J., 2000. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 161, 5e8. Ivask, A., Voelcker, N.H., Seabrook, S.A., Hor, M., Kirby, J., Fenech, M., Davis, T.P., Ke, P.C., 2015. DNA melting and genotoxicity induced by silver nanoparticles and graphene. Chem. Res. Toxicol. 28, 1023e1033. Jacobsen, N.R., Møller, P., Jensen, K.A., Vogel, U., Ladefoged, O., Loft, S., Wallin, H., 2009. Lung inflammation and genotoxicity following pulmonary exposure to nanoparticles in ApoE-/- mice. Part. Fibre Toxicol. 6, 2. http://dx.doi.org/10.1186/ 1743-8977-6-2. Jastrzębska, A.M., Kurtycz, P., Olszyna, A.R., 2012. Recent advances in graphene family materials toxicity investigation. J. Nanopart. Res. 14, 1320. http:// dx.doi.org/10.1007/s11051-012-1320-8. Jim enez, A.S., Brouwer, D., Van Tongeren, M., 2014. Workplace inhalation exposure to engineered nanomaterials. Detection, measurement, and assessment. In: Monteiro-Riviere, N.A., Tran, C.L. (Eds.), Nanotoxicology: Progress toward Nanomedicine, second ed. CRC Press, Boca Raton, pp. 77e96. Kanakia, S., Toussaint, J.D., Chowdhury, S.M., Tembulkar, T., Lee, S., Jiang, Y.P., Lin, R.Z., Shroyer, K.R., Moore, W., Sitharaman, B., 2014. Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formations. Biomaterials 35, 7022e7031. Khan, H., Shanker, R., 2015. Toxicity of nanomaterials. Biomed. Res. Int. http:// dx.doi.org/10.1155/2015/521014. Art ID 521014. Kim, J.K., Shin, J.H., Lee, J.S., Hwang, J.H., Lee, J.H., Baek, J.E., Kim, T.G., Kim, B.W., Kim, J.S., Lee, G.H., Ahn, K., Han, S.G., Bello, D., Yu, I.J., 2016. 28-day inhalation\ntoxicity of graphene nanoplatelets in Sprague-Dawley rats. Nanotoxicology 10, 891e901. Krug, H.F., 2014. Nanosafety research-are we on the right tract? Angew. Chem. Int. 53, 12304e12319. Kurantowicz, N., Strojny, B., Sawosz, E., Jaworski, S., Kutwin, M., Grodzik, M., Wierzbicki, M., Lipi nska, L., Mitura, K., Chwalibog, A., 2015. Biodistribution of a high dose of diamond, graphite, and graphene oxide nanoparticles after multiple intraperitoneal injections in rats. Nanoscale Res. Lett. 10, 398. http:// dx.doi.org/10.1186/s11671-015-1107-9. Lalwani, G., D'Agati, M., Khan, A.M., Sitharaman, B., 2016. Toxicology of graphenebased nanomaterials. Adv. Drug Deliv. Rev. http://dx.doi.org/10.1016/l.addr. 2016.04.028. Lee, J.K., Jeong, A.Y., Bae, J., Seok, J.H., Yang, J.Y., Roh, H.S., Jeong, J., Han, Y., Jeong, J., Cho, W.S., 2016. The role of surface functionalization on the pulmonary inflammogenicity and translocation into mediastinal lymph nodes of graphene nanoplatelets in rats. Arch. Toxicol. http://dx.doi.org/10.1007/s00204-016-1706y. Li, Y., Liu, Y., Fu, Y., Wei, T., Le Guyader, L., Gao, G., Liu, R.S., Chang, Y.Z., Chen, C., 2012. The triggering of apoptosis in macrophages by pristine graphene through the MARK and TGF-beta signaling pathways. Biometerials 33, 402e411. Li, B., Yang, J., Huang, Q., Zhang, Y., Peng, C., Zhang, Y., He, Y., Shi, J., Li, W., Hu, J., Fan, C., 2013. Biodistribution and pulmonary toxicity of intratracheally instilled graphene oxide in mice. APG Asia Mater. 5, e44. http://dx.doi.org/10.1038/ am.2013.7. Li, B., Zhang, X.Y., Yang, J.Z., Zhang, Y.J., Li, W.X., Fan, C.H., Huang, O., 2014. Influence of polyethylene glycol coating on biodistribution and toxicity of nanoscale graphene oxide in mice after intravenous injection. Int. J. Nanomed 9, 4697e4707. Liang, S., Xu, S., Zhang, D., He, J., Chu, M., 2015. Reproductive toxicity of nanoscale graphene oxide in male mice. Nanotoxicology 9, 92e105. Lin, M., Zou, R., Shi, H., Yu, S., Li, X., Guo, R., Yan, L., Li, G., Liu, Y., Dai, L., 2015. Ocular biocompatibility evaluation of hydroxyl-functionalized graphene. Mater. Sci. Eng. C 50, 300e308. Liu, J.H., Yang, S.T., Wang, H., Chang, Y., Cao, A., Liu, Y., 2012. Effect of size and dose on the biodistribution of graphene oxide in mice. Nanomedicine 7, 1801e1812. Liu, Y., Luo, Y., Wu, J., Wang, Y., Yang, X., Yang, R., Wang, B., Yang, J., Zhang, N., 2013. Graphene oxide can induce in vitro and in vivo mutagenesis. Sci. Rep. 3, 3469. http://dx.doi.org/10.1038/srep03469. Liu, J.H., Wang, T., Wang, H., Gu, Y., Xu, Y., Tang, H., Jia, G., Liu, Y., 2015. Biocompatibility of graphene oxide intravenously administered in mice-effects of dose, size and exposure protocols. Toxicol. Res. 4, 83e91. Ma, J., Liu, R., Wang, X., Liu, Q., Chen, Y., Valle, R.P., Zuo, Y.Y., Xia, T., Liu, S., 2015. Crucial role of lateral size for graphene oxide in activating macrophages and stimulating pro-inflammatory responses in cells and animals. ACS Nano 9, 10498e10515. Ma-Hock, L., Strauss, V., Treumann, S., Küttler, K., Wohleben, W., Hofmann, T., Gr€oters, S., Wiench, K., van Ravenzwaay, B., Landsiedel, R., 2013. Comparative inhalation toxicity of multi-wall carbon nanotubes, graphene, graphite nanoplateles and low surface carbon black. Part. Fibre Toxicol. 10, 23. http:// dx.doi.org/10.1186/1743-8977-10-23. Mao, L., Hu, M., Pan, B., Xie, Y., Petersen, E., 2016. Biodistribution and toxicity of radio-labeled few layer graphene in mice after intratracheal instillation. Pat. Fibre Toxical 13, 7. http://dx.doi.org/10.1186/s12989-016-0120-1. Mendonça, M.C.P., Soares, E.S., de Jesus, M.B., Ceragioli, H.S., Irazusta, S.P., Batista, A.G., Vinolo, M.A.R., Júnior, M.R.M., da Cruz-H€ofling, M.A., 2016. Reduced graphene oxide: nanotoxicological profile in rats. J. Nanobiotechnol 14, 53. http://dx.doi.org/10.1186/s12951-0.16-0206-9. Mercer, R.R., Scabilloni, J., Wang, L., Kisin, E., Murray, A.R., Schwegler-Berry, D., Shvedova, A.A., Castranova, V., 2008. Alteration of deposition pattern and pulmonary responses as a result of improved dispersion of aspirated single-walled carbon nanotubes in a mouse model. Am. J. Physiol. Lung Cell Mol. Physiol. 294, L87eL97. Møller, P., Jacobsen, N.R., Folkman, J.K., Danielsen, P.H., Mikkelsen, L., Hemmingsen, J.G., Veatedal, L.K., Forchammer, L., Wallin, H., Loft, S., 2010. Role of oxidative damage in toxicity of particulates. Free Rad. Res. 44, 1e46. Nezakati, T., Cousins, B.G., Seifalian, A.N., 2014. Toxicology of chemically modified graphene-based materials for medical application. Arch. Toxicol. 88, 1987e2012. Novoselov, K.S., Geim, A.K., Morozov, S.V., Jiang, D., Zhang, Y., Dubonos, S.V., Grigorieva, I.V., Firsov, A.A., 2004. Electric field effect in atomically thin carbon films. Science 306, 666e669. Nurunnabi, M., Khatum, Z., Huh, K.M., Park, S.Y., Lee, D.Y., Cho, K.J., Lee, Y., 2013. In vivo biodistribution and toxicology of caboxylated graphene quantum dots. ACS Nano 8, 6858e6867. Park, E.J., Lee, G.H., Han, B.S., Lee, B.S., Cho, M.H., Kim, J.H., Kim, D.W., 2015. Toxic response of graphene nanoplatelets in vivo and in vitro. Arch. Toxicol. 89, 1557e1568. Poland, C.A., Duffin, R., Kinloch, I., Maynard, A., Wallace, W.A.H., Seaton, A., Stone, V., Brown, S., MacNee, W., Donaldson, K., 2008. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol. 3, 423e428. Qiao, Y., An, J., Ma, L., 2013. Single cell array based assay for in vitro genotoxicity study of nanomaterials. Anal. Chem. 85, 4107e4112. Qu, G., Wang, X., Liu, Q., Liu, R., Yin, N., Ma, J., Chen, L., He, J., Liu, S., Jiang, G., 2013a. The ex vivo and in vivo biological performances of graphene oxide and the\nimpact of surfactant on graphene oxide's biocompatibility. J. Environ. Sci. 25, 873e881. Qu, G., Wang, X., Wang, Z., Liu, S., Jiang, G., 2013b. Cytotoxicity of quantum dots and graphene oxide to erythroid cells and macrophages. Nanoscale Res. Lett. 8, 198. http://dx.doi.org/10.1186/1556-276X-8-198. Rothen-Rutishauser, B., Schürch, S., Gehr, P., 2007. Interaction of particles with membranes. In: Donaldson, K., Borm, P. (Eds.), Particle Toxicology. CRC Press, Boca Raton, pp. 139e160. Sanchez, V.C., Jachak, A., Hurt, R.H., Kane, A.B., 2012. Biological interactions of graphene-family nanomaterials: an interdisciplinary review. Chem. Res. Toxicol. 25, 15e34. Sasidharan, A., Swaroop, S., Koduri, C.K., Girish, C.M., Chandran, P., Panchakarla, L.S., Somasundaram, V.H., Gowd, G., Nair, S., Koyakutty, M., 2015. Comparative in vivo toxicity, organ biodistribution and immune response of pristine, carboxylate and PEGylated few-layer graphene sheets in Swiss albino mice: a three month study. Carbon 95, 511e524. Schinwald, A., Murphy, F.A., Jones, A., MacNee, W., Donaldson, K., 2012. Graphenebased nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties. ACS Nano 6, 736e746. Schinwald, A., Murphy, F., Askounis, A., Koutsos, V., Sefiane, K., Donaldson, K., Campbell, C.J., 2014. Minimal oxidation and inflammogenicity of pristine graphene with residence in the lung. Nanotoxicology 8, 824e832. Seabra, A.B., Paula, A.J., de Lima, R., Alves, O.L., Dur an, N., 2014. Nanotoxicity of graphene and graphene oxide. Chem. Res. Toxicol. 27, 159e168. Shin, J.H., Han, S.G., Kim, J.K., Kim, B.W., Hwang, J.H., Lee, J.S., Lee, J.H., Baek, J.E., Kim, T.G., Kim, K.S., Lee, H.H., Song, N.W., Ahn, K., Yu, I.J., 2015. 5-day repeated inhalation and 28-day post-exposure study of graphene. Nanotoxicology 9, 1023e1031. Shvedova, A.A., Kisin, E.R., Mercer, R., Murray, A.R., Johnson, V.J., Gorelik, O., Arepalli, S., Hubbs, A.F., Mercer, R.R., Keohavong, P., Sussman, N., Jin, J.J., Yin, J., Stone, B., Chen, B.T., Deye, G., Maynard, A., Castranova, V., Baron, P., Kagan, V.E., 2008. Inhalation vs. aspiration of single-walled carbon nanotubes in C57BL/6 mice: inflammation, fibrosis, oxidative stress, and mutagenesis. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L552eL565. Shvedova, A.A., Yanamala, N., Kisin, E.R., Tkach, A.V., Murray, A.R., Hubbs, A., Chirila, M.M., Keohavong, P., Sycheva, L.P., Kagan, V.A., Castranova, V., 2014. Long-term effects of carbon containing nanomaterials and asbestos in the lung: one year postexposure comparisons. Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L170eL182. Shvedova, A., Pietroiusti, A., Kagan, V., 2016. Nanotoxicology ten years later: lights and shadows. Toxicol. Appl. Pharmacol. 299, 1e2. Singh, S.K., Singh, M.K., Nayaka, M.K., Kumari, S., Shrivastava, S., Gr acio, J.A., Dash, D., 2011. Thronbus inducing property of atomically thin graphene oxide sheets. ACS Nano 5, 4987e4886. Singh, S.K., Singh, M.K., Kumari, S., Sonkar, V.K., Gr acio, J.A., Dash, D., 2012. Aminemodified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications. ACS Nano 6, 2731e2740. Stone, V., Johnston, H., Schins, R.P., 2009. Development of in vitro systems for nanotoxicology: methodological considerations. Crit. Rev. Toxicol. 39, 613e626. Strojny, B., Kurantowicz, N., Sawosz, E., Grodzik, M., Jaworski, S., Kutwin, M., Wierzbicki, M., Hotowy, A., Lipi nska, L., Chwalibog, A., 2015. Long term influence of carbon nanoparticles on health and liver status in rats. PLos One 10 (12), e0144821. http://dx.doi.org/10.1371/journal.pone.0144821.\nWang, K., Ruan, J., Song, H., Zhang, J., Wo, Y., Guo, S., Cui, D., 2011. Biocompatibility of graphene oxide. Nanoscale Res. Lett. 6, 8. http://dx.doi.org/10.1007/s11671010-9751-6. Wang, X., Podila, R., Shannahan, J.H., Rao, A.M., Brown, J.M., 2013a. Intravenously delivered graphene nanosheets and multiwalled carbon nanotubes induce sitespecific Th2 inflammatory responses via the IL-33/ST2 axis. Int. J. Nanomed 8, 1733e1748. Wang, A., Pu, K., Dong, B., Liu, Y., Zhang, L., Zhang, Z., Duan, W., Zhu, Y., 2013b. Role of surface charge and oxidative stress in cytotoxicity and genotoxicity of graphene oxide towards human lung fibroblast cells. J. Appl. Toxicol. 33, 1156e1164. Wang, X., Duch, M.C., Mansukhani, N., Ji, Z., Liao, Y.P., Zhang, H., Sun, B., Chang, C.H., Li, S., Meng, H., Xia, T., Hersam, M.C., Nel, A., 2015a. Use of a pro-fibrogenic mechanism-based predictive toxicological approach for tiered testing and decision analysis of carbonaceous nanomaterials. ACS Nano 9, 3032e3043. Wang, D., Zhu, L., Chen, J.F., Dai, L., 2015b. Can graphene quantum dots cause DNA damage in cells? Nanoscale 7, 9894e9901. Wen, K.P., Chen, Y.C., Chuang, C.H., Chang, H.Y., Lee, C.Y., Tai, N.H., 2015. Accumulation and toxicity of intravenously-injected functionalized graphene oxide in mice. J. Appl. Toxicol. 35, 1211e1218. Wu, W., Yan, L., Wu, Q., Li, Y., Li, Q., Chen, S., Yang, Y., Gu, Z., Yin, Z.Q., 2016. Evaluation of the toxicity of graphene oxide exposure to the eye. Nanotoxicology 10, 1329e1340. Xu, C., Wang, J., Xu, Y., Shang, G., Wang, R., Lin, Y., 2013. Review of and perspectives on the toxicology of graphene-based materials. Curr. Drug Metab. 14, 863e871. Xu, S., Zhang, Z., Chu, M., 2015. Long-term toxicity of reduced graphene oxide nanosheets: effects on female mouse reproductive ability and offspring development. Biometerials 54, 188e200. Xu, M., Zhu, J., Wang, F., Xiong, Y., Wu, Y., Wang, Q., Weng, J., Zhang, Z., Chen, W., Liu, S., 2016. Improved in vitro and in vivo biocompatibility of graphene oxide through surface modification: poly(acrylic acid)-functionalization is superior to PEGylation. ACS Nano 10, 3267e3281. Yan, L., Wang, Y., Xu, X., Zeng, C., Hou, J., Lin, M., Xu, J., Sun, F., Huang, x., Dai, L., Lu, F., Liu, Y., 2012. Can graphene oxide cause damage to eyesight? Chem. Res. Toxicol. 25, 1265e1270. Yang, K., Wan, J., Zhang, S., Zhang, Y., Lee, S.T., Liu, Z., 2011. In vitro pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice. ACS Nano 5, 516e522. Yang, K., Gong, H., Shi, X., Wan, J., Zhang, Y., Liu, Z., 2013. In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. Biomaterials 34, 2787e2795. Zhang, Y., Ali, S.F., Dervishi, E., Xu, Y., Li, Z., Casciano, D., Biris, A., 2010. Cytotoxicity effects of graphene and single-wall carbon nanotubes in neural phaeochromocytoma-derived PC12 cells. ACS Nano 6, 3181e3186. Zhang, S., Yang, K., Feng, L., Liu, Z., 2011a. In vitro and in vivo behaviors of dextran functionalized graphene. Carbon 49, 4040e4049. Zhang, X., Yin, J., Peng, C., Hu, W., Zhu, Z., Li, W., Fan, C., Huang, Q., 2011b. Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon 49, 986e995. Zhang, D., Zhang, Z., Liu, Y., Chu, M., Yang, C., Li, W., Shao, Y., Yue, Y., Xu, R., 2015. The short- and long-term effects of orally administered high-dose reduced graphene oxide nanosheets on mouse behaviors. Biomaterials 68, 100e113."
    } ],
    "references" : [ {
      "title" : "Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2017.01.011",
      "author" : [ "O. Akhavan", "E. Ghaderi", "A. Akhavan" ],
      "venue" : null,
      "citeRegEx" : "Akhavan et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Akhavan et al\\.",
      "year" : 2012
    }, {
      "title" : "Purified graphene oxide dispersions lack in vitro cytotox",
      "author" : [ "K. Kostarelos" ],
      "venue" : null,
      "citeRegEx" : "Kostarelos,? \\Q2013\\E",
      "shortCiteRegEx" : "Kostarelos",
      "year" : 2013
    }, {
      "title" : "Case studies putting the decision-making framework",
      "author" : [ "R. Landsiedel" ],
      "venue" : null,
      "citeRegEx" : "Landsiedel,? \\Q2016\\E",
      "shortCiteRegEx" : "Landsiedel",
      "year" : 2016
    }, {
      "title" : "Equivalent titanium dioxide nanoparticle deposition",
      "author" : [ "A. Elder" ],
      "venue" : null,
      "citeRegEx" : "Elder,? \\Q2014\\E",
      "shortCiteRegEx" : "Elder",
      "year" : 2014
    }, {
      "title" : "No cytotoxicity or genotoxicity of graphene and graphene oxide",
      "author" : [ "U. Vogel" ],
      "venue" : null,
      "citeRegEx" : "Vogel,? \\Q2016\\E",
      "shortCiteRegEx" : "Vogel",
      "year" : 2016
    }, {
      "title" : "Differential genotoxic and epigenotoxic",
      "author" : [ "N. 642e649. Chatterjee", "J.S. Yang", "J. Choi" ],
      "venue" : null,
      "citeRegEx" : "Chatterjee et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Chatterjee et al\\.",
      "year" : 2016
    }, {
      "title" : "Asbestos, carbon nanotubes",
      "author" : [ "K. Donaldson", "F.A. Murphy", "R. Duffin", "C. Poland" ],
      "venue" : "toxicity. Curr. Opin. Biotechnol",
      "citeRegEx" : "Donaldson et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Donaldson et al\\.",
      "year" : 2010
    }, {
      "title" : "patibility of graphene in the lung",
      "author" : [ "M. Ema", "M. Gamo", "K. Honda" ],
      "venue" : "Nano Lett. 11,",
      "citeRegEx" : "Ema et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Ema et al\\.",
      "year" : 2016
    }, {
      "title" : "carbon nanotubes in laboratory animals",
      "author" : [ "K.S. Hougaard", "A. Kishimoto", "K. Honda" ],
      "venue" : "Regul. Toxicol. Pharmacol",
      "citeRegEx" : "M. et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "M. et al\\.",
      "year" : 2016
    }, {
      "title" : "Effects of graphene oxide",
      "author" : [ "C. Fu", "T. Liu", "L. Li", "H. Liu", "Q. Liang", "X. Meng" ],
      "venue" : null,
      "citeRegEx" : "Fu et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Fu et al\\.",
      "year" : 2015
    }, {
      "title" : "Manufactured nanomaterials: categorization and approaches to hazard assessment",
      "author" : [ "C. ohl", "T. Schupp", "C. Weiss", "K.M. Wollin", "J.G. Hengstler" ],
      "venue" : "Arch. Toxicol",
      "citeRegEx" : "ohl et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "ohl et al\\.",
      "year" : 2014
    }, {
      "title" : "Assessment of the toxic potential of graphene family nanomaterials",
      "author" : [ "X. Guo", "N. Mei" ],
      "venue" : "J. Food Drug Anal",
      "citeRegEx" : "Guo and Mei,? \\Q2014\\E",
      "shortCiteRegEx" : "Guo and Mei",
      "year" : 2014
    }, {
      "title" : "Pulmonary responses of Sprague-Dawley rats in single inhalation exposure to graphene oxide nanomaterials",
      "author" : [ "S.G. Han", "J.K. Kim", "J.H. Shin", "J.H. Hwang", "J.S. Lee", "T.G. Kim", "J.H. Lee", "G.H. Lee", "K.S. Kim", "H.S. Lee", "N.W. Song", "K. Ahm", "I.J. Yu" ],
      "venue" : "Biomed. Res. Int. Article ID",
      "citeRegEx" : "Han et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Han et al\\.",
      "year" : 2015
    }, {
      "title" : "Synthesis and cyto-genotoxicity evaluation of graphene on mice spermatogonia stem cells",
      "author" : [ "E. Hashemi", "O. Akhavan", "M. Shamsara", "M. Daliri", "M. Dashtizad", "A. Farmany" ],
      "venue" : "Colloids Surf. B Biointerfaces",
      "citeRegEx" : "Hashemi et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Hashemi et al\\.",
      "year" : 2016
    }, {
      "title" : "Protein corona-mediated mitigation of cytotoxicity of graphene oxide",
      "author" : [ "W. Hu", "C. Peng", "M. Lv", "X. Li", "Y. Zhang", "N. Chen", "C. Fan", "Q. Huang" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Hu et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Hu et al\\.",
      "year" : 2011
    }, {
      "title" : "Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study",
      "author" : [ "R. Hubbard", "A. Venn", "S. Lewis", "J. Britton" ],
      "venue" : "Am. J. Respir. Crit. Care Med",
      "citeRegEx" : "Hubbard et al\\.,? \\Q2000\\E",
      "shortCiteRegEx" : "Hubbard et al\\.",
      "year" : 2000
    }, {
      "title" : "DNA melting and genotoxicity induced by silver nanoparticles and graphene",
      "author" : [ "A. Ivask", "N.H. Voelcker", "S.A. Seabrook", "M. Hor", "J. Kirby", "M. Fenech", "T.P. Davis", "P.C. Ke" ],
      "venue" : "Chem. Res. Toxicol",
      "citeRegEx" : "Ivask et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Ivask et al\\.",
      "year" : 2015
    }, {
      "title" : "Lung inflammation and genotoxicity following pulmonary exposure to nanoparticles in ApoE-/- mice",
      "author" : [ "N.R. Jacobsen", "P. Møller", "K.A. Jensen", "U. Vogel", "O. Ladefoged", "S. Loft", "H. Wallin" ],
      "venue" : "Part. Fibre Toxicol",
      "citeRegEx" : "Jacobsen et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Jacobsen et al\\.",
      "year" : 2009
    }, {
      "title" : "Recent advances in graphene family materials toxicity investigation",
      "author" : [ "A.M. Jastrzębska", "P. Kurtycz", "A.R. Olszyna" ],
      "venue" : "J. Nanopart. Res",
      "citeRegEx" : "Jastrzębska et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Jastrzębska et al\\.",
      "year" : 2012
    }, {
      "title" : "Workplace inhalation exposure to engineered nanomaterials. Detection, measurement, and assessment",
      "author" : [ "A.S. Jim enez", "D. Brouwer", "M. Van Tongeren" ],
      "venue" : null,
      "citeRegEx" : "enez et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "enez et al\\.",
      "year" : 2014
    }, {
      "title" : "Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formations. Biomaterials 35, 7022e7031",
      "author" : [ "S. Kanakia", "J.D. Toussaint", "S.M. Chowdhury", "T. Tembulkar", "S. Lee", "Y.P. Jiang", "R.Z. Lin", "K.R. Shroyer", "W. Moore", "B. Sitharaman" ],
      "venue" : null,
      "citeRegEx" : "Kanakia et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Kanakia et al\\.",
      "year" : 2014
    }, {
      "title" : "Toxicity of nanomaterials",
      "author" : [ "H. Khan", "R. Shanker" ],
      "venue" : "Biomed. Res. Int. http:// dx.doi.org/10.1155/2015/521014. Art ID 521014",
      "citeRegEx" : "Khan and Shanker,? \\Q2015\\E",
      "shortCiteRegEx" : "Khan and Shanker",
      "year" : 2015
    }, {
      "title" : "28-day inhalation",
      "author" : [ "J.K. Kim", "J.H. Shin", "J.S. Lee", "J.H. Hwang", "J.H. Lee", "J.E. Baek", "T.G. Kim", "B.W. Kim", "J.S. Kim", "G.H. Lee", "K. Ahn", "S.G. Han", "D. Bello", "I.J. Yu" ],
      "venue" : null,
      "citeRegEx" : "Kim et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Kim et al\\.",
      "year" : 2016
    }, {
      "title" : "Nanosafety research-are we on the right tract",
      "author" : [ "H.F. Krug" ],
      "venue" : "Angew. Chem. Int",
      "citeRegEx" : "Krug,? \\Q2014\\E",
      "shortCiteRegEx" : "Krug",
      "year" : 2014
    }, {
      "title" : "Biodistribution of a high dose of diamond, graphite, and graphene oxide nanoparticles after multiple intraperitoneal injections in rats",
      "author" : [ "N. Kurantowicz", "B. Strojny", "E. Sawosz", "S. Jaworski", "M. Kutwin", "M. Grodzik", "M. Wierzbicki", "L. Lipi nska", "K. Mitura", "A. Chwalibog" ],
      "venue" : "Nanoscale Res",
      "citeRegEx" : "Kurantowicz et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Kurantowicz et al\\.",
      "year" : 2015
    }, {
      "title" : "Toxicology of graphenebased nanomaterials",
      "author" : [ "G. Lalwani", "M. D'Agati", "A.M. Khan", "B. Sitharaman" ],
      "venue" : "Adv. Drug Deliv. Rev",
      "citeRegEx" : "Lalwani et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Lalwani et al\\.",
      "year" : 2016
    }, {
      "title" : "The role of surface functionalization on the pulmonary inflammogenicity and translocation into mediastinal lymph nodes of graphene nanoplatelets in rats",
      "author" : [ "J.K. Lee", "A.Y. Jeong", "J. Bae", "J.H. Seok", "J.Y. Yang", "H.S. Roh", "J. Jeong", "Y. Han", "W.S. Cho" ],
      "venue" : "Arch. Toxicol. http://dx.doi.org/10.1007/s00204-016-1706y",
      "citeRegEx" : "Lee et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2016
    }, {
      "title" : "The triggering of apoptosis in macrophages by pristine graphene through the MARK and TGF-beta signaling pathways",
      "author" : [ "Y. Li", "Y. Liu", "Y. Fu", "T. Wei", "L. Le Guyader", "G. Gao", "R.S. Liu", "Y.Z. Chang", "C. Chen" ],
      "venue" : "Biometerials 33,",
      "citeRegEx" : "Li et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2012
    }, {
      "title" : "Biodistribution and pulmonary toxicity of intratracheally instilled graphene oxide in mice",
      "author" : [ "B. Li", "J. Yang", "Q. Huang", "Y. Zhang", "C. Peng", "Y. He", "J. Shi", "W. Li", "J. Hu", "C. Fan" ],
      "venue" : "APG Asia Mater",
      "citeRegEx" : "Li et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2013
    }, {
      "title" : "Influence of polyethylene glycol coating on biodistribution and toxicity of nanoscale graphene oxide in mice after intravenous injection",
      "author" : [ "B. Li", "X.Y. Zhang", "J.Z. Yang", "Y.J. Zhang", "W.X. Li", "C.H. Fan", "O. Huang" ],
      "venue" : "Int. J. Nanomed",
      "citeRegEx" : "Li et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2014
    }, {
      "title" : "Reproductive toxicity of nanoscale graphene oxide in male mice",
      "author" : [ "S. Liang", "S. Xu", "D. Zhang", "J. He", "M. Chu" ],
      "venue" : "Nanotoxicology",
      "citeRegEx" : "Liang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Liang et al\\.",
      "year" : 2015
    }, {
      "title" : "Ocular biocompatibility evaluation of hydroxyl-functionalized graphene",
      "author" : [ "M. Lin", "R. Zou", "H. Shi", "S. Yu", "X. Li", "R. Guo", "L. Yan", "G. Li", "Y. Liu", "L. Dai" ],
      "venue" : "Mater. Sci. Eng. C",
      "citeRegEx" : "Lin et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Lin et al\\.",
      "year" : 2015
    }, {
      "title" : "Effect of size and dose on the biodistribution of graphene oxide in mice",
      "author" : [ "J.H. Liu", "S.T. Yang", "H. Wang", "Y. Chang", "A. Cao", "Y. Liu" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "Liu et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2012
    }, {
      "title" : "Graphene oxide can induce in vitro and in vivo mutagenesis",
      "author" : [ "Y. Liu", "Y. Luo", "J. Wu", "Y. Wang", "X. Yang", "R. Yang", "B. Wang", "J. Yang", "N. Zhang" ],
      "venue" : "http://dx.doi.org/10.1038/srep03469",
      "citeRegEx" : "Liu et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2013
    }, {
      "title" : "Biocompatibility of graphene oxide intravenously administered in mice-effects of dose, size and exposure",
      "author" : [ "J.H. Liu", "T. Wang", "H. Wang", "Y. Gu", "Y. Xu", "H. Tang", "G. Jia", "Y. Liu" ],
      "venue" : "protocols. Toxicol. Res",
      "citeRegEx" : "Liu et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2015
    }, {
      "title" : "Crucial role of lateral size for graphene oxide in activating macrophages and stimulating pro-inflammatory responses in cells and animals",
      "author" : [ "J. Ma", "R. Liu", "X. Wang", "Q. Liu", "Y. Chen", "R.P. Valle", "Y.Y. Zuo", "T. Xia", "S. Liu" ],
      "venue" : "ACS Nano 9,",
      "citeRegEx" : "Ma et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Ma et al\\.",
      "year" : 2015
    }, {
      "title" : "Comparative inhalation toxicity of multi-wall carbon nanotubes, graphene, graphite nanoplateles and low surface carbon black",
      "author" : [ "S. oters", "K. Wiench", "B. van Ravenzwaay", "R. Landsiedel" ],
      "venue" : "Part. Fibre Toxicol",
      "citeRegEx" : "oters et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "oters et al\\.",
      "year" : 2013
    }, {
      "title" : "Biodistribution and toxicity of radio-labeled few layer graphene in mice after intratracheal instillation",
      "author" : [ "L. Mao", "M. Hu", "B. Pan", "Y. Xie", "E. Petersen" ],
      "venue" : "Pat. Fibre Toxical 13,",
      "citeRegEx" : "Mao et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Mao et al\\.",
      "year" : 2016
    }, {
      "title" : "Alteration of deposition pattern and pul",
      "author" : [ "A.A. Shvedova", "V. Castranova" ],
      "venue" : null,
      "citeRegEx" : "Shvedova and Castranova,? \\Q2008\\E",
      "shortCiteRegEx" : "Shvedova and Castranova",
      "year" : 2008
    }, {
      "title" : "oxidative damage in toxicity of particulates",
      "author" : [ "T. Nezakati", "B.G. Cousins", "A.N. Seifalian" ],
      "venue" : "Free Rad. Res",
      "citeRegEx" : "Nezakati et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Nezakati et al\\.",
      "year" : 2014
    }, {
      "title" : "Electric field effect in atomically thin carbon",
      "author" : [ "I.V. Grigorieva", "A.A. Firsov" ],
      "venue" : null,
      "citeRegEx" : "Grigorieva and Firsov,? \\Q2004\\E",
      "shortCiteRegEx" : "Grigorieva and Firsov",
      "year" : 2004
    }, {
      "title" : "Carbon nanotubes",
      "author" : [ "S. Brown", "W. MacNee", "K. Donaldson" ],
      "venue" : null,
      "citeRegEx" : "Brown et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Brown et al\\.",
      "year" : 2008
    }, {
      "title" : "Single cell array based assay for in vitro genotoxicity",
      "author" : [ "Nat. Nanotechnol", "Y. 423e428. Qiao", "J. An", "L. Ma" ],
      "venue" : null,
      "citeRegEx" : "3 et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "3 et al\\.",
      "year" : 2013
    }, {
      "title" : "Cytotoxicity of quantum dots and graphene oxide to erythroid cells and macrophages",
      "author" : [ "G. Qu", "X. Wang", "Z. Wang", "S. Liu", "G. Jiang" ],
      "venue" : "Nanoscale Res. Lett",
      "citeRegEx" : "Qu et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Qu et al\\.",
      "year" : 2013
    }, {
      "title" : "Interaction of particles with membranes",
      "author" : [ "B. Rothen-Rutishauser", "S. Schürch", "P. Gehr" ],
      "venue" : "Particle Toxicology. CRC Press, Boca Raton, pp. 139e160",
      "citeRegEx" : "Rothen.Rutishauser et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Rothen.Rutishauser et al\\.",
      "year" : 2007
    }, {
      "title" : "Biological interactions of graphene-family nanomaterials: an interdisciplinary review",
      "author" : [ "V.C. Sanchez", "A. Jachak", "R.H. Hurt", "A.B. Kane" ],
      "venue" : "Chem. Res. Toxicol",
      "citeRegEx" : "Sanchez et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Sanchez et al\\.",
      "year" : 2012
    }, {
      "title" : "Comparative in vivo toxicity, organ biodistribution and immune response of pristine, carboxylate and PEGylated few-layer graphene sheets in Swiss albino mice: a three month study",
      "author" : [ "A. Sasidharan", "S. Swaroop", "C.K. Koduri", "C.M. Girish", "P. Chandran", "L.S. Panchakarla", "V.H. Somasundaram", "G. Gowd", "S. Nair", "M. Koyakutty" ],
      "venue" : "Carbon 95,",
      "citeRegEx" : "Sasidharan et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Sasidharan et al\\.",
      "year" : 2015
    }, {
      "title" : "Graphenebased nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties",
      "author" : [ "A. Schinwald", "F.A. Murphy", "A. Jones", "W. MacNee", "K. Donaldson" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Schinwald et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Schinwald et al\\.",
      "year" : 2012
    }, {
      "title" : "Minimal oxidation and inflammogenicity of pristine graphene with residence in the lung",
      "author" : [ "A. Schinwald", "F. Murphy", "A. Askounis", "V. Koutsos", "K. Sefiane", "K. Donaldson", "C.J. Campbell" ],
      "venue" : "Nanotoxicology",
      "citeRegEx" : "Schinwald et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Schinwald et al\\.",
      "year" : 2014
    }, {
      "title" : "Nanotoxicity of graphene and graphene oxide",
      "author" : [ "A.B. Seabra", "A.J. Paula", "R. de Lima", "O.L. Alves", "N. Dur an" ],
      "venue" : "Chem. Res. Toxicol",
      "citeRegEx" : "Seabra et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Seabra et al\\.",
      "year" : 2014
    }, {
      "title" : "5-day repeated inhalation and 28-day post-exposure study of graphene",
      "author" : [ "J.H. Shin", "S.G. Han", "J.K. Kim", "B.W. Kim", "J.H. Hwang", "J.S. Lee", "J.H. Lee", "J.E. Baek", "T.G. Kim", "K.S. Kim", "H.H. Lee", "N.W. Song", "K. Ahn", "I.J. Yu" ],
      "venue" : "Nanotoxicology 9,",
      "citeRegEx" : "Shin et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Shin et al\\.",
      "year" : 2015
    }, {
      "title" : "Inhalation vs. aspiration of single-walled carbon nanotubes in C57BL/6 mice: inflammation, fibrosis, oxidative stress, and mutagenesis",
      "author" : [ "A.A. Shvedova", "E.R. Kisin", "R. Mercer", "A.R. Murray", "V.J. Johnson", "O. Gorelik", "S. Arepalli", "A.F. Hubbs", "R.R. Mercer", "P. Keohavong", "N. Sussman", "J.J. Jin", "J. Yin", "B. Stone", "B.T. Chen", "G. Deye", "A. Maynard", "V. Castranova", "P. Baron", "V.E. Kagan" ],
      "venue" : "Am. J. Physiol",
      "citeRegEx" : "Shvedova et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Shvedova et al\\.",
      "year" : 2008
    }, {
      "title" : "Long-term effects of carbon containing nanomaterials and asbestos in the lung: one year postexposure comparisons",
      "author" : [ "A.A. Shvedova", "N. Yanamala", "E.R. Kisin", "A.V. Tkach", "A.R. Murray", "A. Hubbs", "M.M. Chirila", "P. Keohavong", "L.P. Sycheva", "V.A. Kagan", "V. Castranova" ],
      "venue" : "Am. J. Physiol. Lung Cell. Mol. Physiol",
      "citeRegEx" : "Shvedova et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Shvedova et al\\.",
      "year" : 2014
    }, {
      "title" : "Nanotoxicology ten years later: lights and shadows",
      "author" : [ "A. Shvedova", "A. Pietroiusti", "V. Kagan" ],
      "venue" : "Toxicol. Appl. Pharmacol. 299,",
      "citeRegEx" : "Shvedova et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Shvedova et al\\.",
      "year" : 2016
    }, {
      "title" : "Thronbus inducing property of atomically thin graphene oxide sheets",
      "author" : [ "S.K. Singh", "M.K. Singh", "M.K. Nayaka", "S. Kumari", "S. Shrivastava", "J.A. Gr acio", "D. Dash" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Singh et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Singh et al\\.",
      "year" : 2011
    }, {
      "title" : "Aminemodified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications",
      "author" : [ "S.K. Singh", "M.K. Singh", "S. Kumari", "V.K. Sonkar", "J.A. Gr acio", "D. Dash" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Singh et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Singh et al\\.",
      "year" : 2012
    }, {
      "title" : "Development of in vitro systems for nanotoxicology: methodological considerations",
      "author" : [ "V. Stone", "H. Johnston", "R.P. Schins" ],
      "venue" : "Crit. Rev. Toxicol",
      "citeRegEx" : "Stone et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Stone et al\\.",
      "year" : 2009
    }, {
      "title" : "Long term influence of carbon nanoparticles on health and liver status in rats",
      "author" : [ "B. Strojny", "N. Kurantowicz", "E. Sawosz", "M. Grodzik", "S. Jaworski", "M. Kutwin", "M. Wierzbicki", "A. Hotowy", "L. Lipi nska", "A. Chwalibog" ],
      "venue" : "PLos One 10 (12),",
      "citeRegEx" : "Strojny et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Strojny et al\\.",
      "year" : 2015
    }, {
      "title" : "Biocompatibility of graphene oxide",
      "author" : [ "K. Wang", "J. Ruan", "H. Song", "J. Zhang", "Y. Wo", "S. Guo", "D. Cui" ],
      "venue" : "Nanoscale Res. Lett. 6,",
      "citeRegEx" : "Wang et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2011
    }, {
      "title" : "Intravenously delivered graphene nanosheets and multiwalled carbon nanotubes induce sitespecific Th2 inflammatory responses via the IL-33/ST2 axis",
      "author" : [ "X. Wang", "R. Podila", "J.H. Shannahan", "A.M. Rao", "J.M. Brown" ],
      "venue" : "Int. J. Nanomed",
      "citeRegEx" : "Wang et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2013
    }, {
      "title" : "Role of surface charge and oxidative stress in cytotoxicity and genotoxicity of graphene oxide towards human lung fibroblast cells",
      "author" : [ "A. Wang", "K. Pu", "B. Dong", "Y. Liu", "L. Zhang", "Z. Zhang", "W. Duan", "Y. Zhu" ],
      "venue" : "J. Appl. Toxicol",
      "citeRegEx" : "Wang et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2013
    }, {
      "title" : "2015a. Use of a pro-fibrogenic mechanism-based predictive toxicological approach for tiered testing and decision analysis of carbonaceous nanomaterials",
      "author" : [ "X. Wang", "M.C. Duch", "N. Mansukhani", "Z. Ji", "Y.P. Liao", "H. Zhang", "B. Sun", "C.H. Chang", "S. Li", "H. Meng", "T. Xia", "M.C. Hersam", "A. Nel" ],
      "venue" : "ACS Nano 9,",
      "citeRegEx" : "Wang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2015
    }, {
      "title" : "2015b. Can graphene quantum dots cause DNA damage in cells",
      "author" : [ "D. Wang", "L. Zhu", "J.F. Chen", "L. Dai" ],
      "venue" : "Nanoscale 7,",
      "citeRegEx" : "Wang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2015
    }, {
      "title" : "Accumulation and toxicity of intravenously-injected functionalized graphene oxide in mice",
      "author" : [ "K.P. Wen", "Y.C. Chen", "C.H. Chuang", "H.Y. Chang", "C.Y. Lee", "N.H. Tai" ],
      "venue" : "J. Appl. Toxicol",
      "citeRegEx" : "Wen et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Wen et al\\.",
      "year" : 2015
    }, {
      "title" : "Evaluation of the toxicity of graphene oxide exposure to the eye",
      "author" : [ "W. Wu", "L. Yan", "Q. Wu", "Y. Li", "Q. Li", "S. Chen", "Y. Yang", "Z. Gu", "Z.Q. Yin" ],
      "venue" : "Nanotoxicology 10,",
      "citeRegEx" : "Wu et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Wu et al\\.",
      "year" : 2016
    }, {
      "title" : "Review of and perspectives on the toxicology of graphene-based materials",
      "author" : [ "C. Xu", "J. Wang", "Y. Xu", "G. Shang", "R. Wang", "Y. Lin" ],
      "venue" : "Curr. Drug Metab",
      "citeRegEx" : "Xu et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Xu et al\\.",
      "year" : 2013
    }, {
      "title" : "Long-term toxicity of reduced graphene oxide nanosheets: effects on female mouse reproductive ability and offspring development",
      "author" : [ "S. Xu", "Z. Zhang", "M. Chu" ],
      "venue" : "Biometerials 54,",
      "citeRegEx" : "Xu et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Xu et al\\.",
      "year" : 2015
    }, {
      "title" : "Improved in vitro and in vivo biocompatibility of graphene oxide through surface modification: poly(acrylic acid)-functionalization is superior to PEGylation",
      "author" : [ "M. Xu", "J. Zhu", "F. Wang", "Y. Xiong", "Y. Wu", "Q. Wang", "J. Weng", "Z. Zhang", "W. Chen", "S. Liu" ],
      "venue" : "ACS Nano 10,",
      "citeRegEx" : "Xu et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Xu et al\\.",
      "year" : 2016
    }, {
      "title" : "Can graphene oxide cause damage to eyesight",
      "author" : [ "L. Yan", "Y. Wang", "X. Xu", "C. Zeng", "J. Hou", "M. Lin", "J. Xu", "F. Sun", "Huang", "L. Dai", "F. Lu", "Y. Liu" ],
      "venue" : "Chem. Res. Toxicol",
      "citeRegEx" : "Yan et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Yan et al\\.",
      "year" : 2012
    }, {
      "title" : "In vitro pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice",
      "author" : [ "K. Yang", "J. Wan", "S. Zhang", "Y. Zhang", "S.T. Lee", "Z. Liu" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Yang et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2011
    }, {
      "title" : "In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration",
      "author" : [ "K. Yang", "H. Gong", "X. Shi", "J. Wan", "Y. Zhang", "Z. Liu" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "Yang et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2013
    }, {
      "title" : "Cytotoxicity effects of graphene and single-wall carbon nanotubes in neural phaeochromocytoma-derived PC12 cells",
      "author" : [ "Y. Zhang", "S.F. Ali", "E. Dervishi", "Y. Xu", "Z. Li", "D. Casciano", "A. Biris" ],
      "venue" : "ACS Nano",
      "citeRegEx" : "Zhang et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2010
    }, {
      "title" : "In vitro and in vivo behaviors of dextran functionalized graphene",
      "author" : [ "S. Zhang", "K. Yang", "L. Feng", "Z. Liu" ],
      "venue" : "Carbon 49,",
      "citeRegEx" : "Zhang et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2011
    }, {
      "title" : "Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration",
      "author" : [ "X. Zhang", "J. Yin", "C. Peng", "W. Hu", "Z. Zhu", "W. Li", "C. Fan", "Q. Huang" ],
      "venue" : "Carbon 49,",
      "citeRegEx" : "Zhang et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2011
    }, {
      "title" : "The short- and long-term effects of orally administered high-dose reduced graphene oxide nanosheets on mouse",
      "author" : [ "D. Zhang", "Z. Zhang", "Y. Liu", "M. Chu", "C. Yang", "W. Li", "Y. Shao", "Y. Yue", "R. Xu" ],
      "venue" : "behaviors. Biomaterials",
      "citeRegEx" : "Zhang et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2015
    } ],
    "referenceMentions" : [ {
      "referenceID" : 49,
      "context" : "Graphene (GP) is the new allotrope of carbon and is defined as a single layer of monocrystalline graphite with sp2-hybridized carbon atoms tightly packed in a two-dimensional honeycomb lattice, resulting in a large surface area on both sides of the planar axis (Duch et al., 2011; Bianco, 2013; Seabra et al., 2014).",
      "startOffset" : 261,
      "endOffset" : 315
    }, {
      "referenceID" : 45,
      "context" : "GP-based NMs (GNMs) include single-layer GP, few-layer GP (2e10 layers), GP oxide (GO) (normally a single layer), reduced GO (rGO) (normally a single layer), GP nanosheets, GP ribbons, and GP quantum dots (GQDs) (Sanchez et al., 2012; Bianco, 2013).",
      "startOffset" : 212,
      "endOffset" : 248
    }, {
      "referenceID" : 18,
      "context" : "GNMs have unique electronic andmechanical properties, specificmagnetism, excellent mobility of charge carriers, high thermal conductivity, a large surface area, excellent conductivity, outstanding mechanical strength, and extraordinary electrocatalytic activity (Jastrzębska et al., 2012), as well as potential biocompatibility, which make them attractive candidates for biomedical applications including electrochemical devices, energy storage, absorption of enzymes, cell imaging, drug delivery, and biosensors (Xu et al.",
      "startOffset" : 262,
      "endOffset" : 288
    }, {
      "referenceID" : 65,
      "context" : ", 2012), as well as potential biocompatibility, which make them attractive candidates for biomedical applications including electrochemical devices, energy storage, absorption of enzymes, cell imaging, drug delivery, and biosensors (Xu et al., 2013).",
      "startOffset" : 232,
      "endOffset" : 249
    }, {
      "referenceID" : 18,
      "context" : "To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016).",
      "startOffset" : 82,
      "endOffset" : 246
    }, {
      "referenceID" : 45,
      "context" : "To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016).",
      "startOffset" : 82,
      "endOffset" : 246
    }, {
      "referenceID" : 65,
      "context" : "To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016).",
      "startOffset" : 82,
      "endOffset" : 246
    }, {
      "referenceID" : 11,
      "context" : "To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016).",
      "startOffset" : 82,
      "endOffset" : 246
    }, {
      "referenceID" : 39,
      "context" : "To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016).",
      "startOffset" : 82,
      "endOffset" : 246
    }, {
      "referenceID" : 49,
      "context" : "To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016).",
      "startOffset" : 82,
      "endOffset" : 246
    }, {
      "referenceID" : 25,
      "context" : "To date, several review papers regarding the toxicity of GNMs have been published (Jastrzębska et al., 2012; Sanchez et al., 2012; Bianco, 2013; Xu et al., 2013; Guo and Mei, 2014; Nezakati et al., 2014; Seabra et al., 2014; Lalwani et al., 2016).",
      "startOffset" : 82,
      "endOffset" : 246
    }, {
      "referenceID" : 53,
      "context" : "It is very important, from time to time, to take a break and summarize and re-assess the accumulating data, because ongoing and future research alongwith new findings are the only productive ways to assess risks and potential hazards associated with the use of newmaterials (Shvedova et al., 2016).",
      "startOffset" : 274,
      "endOffset" : 297
    }, {
      "referenceID" : 50,
      "context" : "Rats inhaled GP for 5 days, 6 h/day (Shin et al., 2015).",
      "startOffset" : 36,
      "endOffset" : 55
    }, {
      "referenceID" : 22,
      "context" : "Rats inhaled GP for 4 weeks, 6 h/day and 5 days/week (Kim et al., 2016).",
      "startOffset" : 53,
      "endOffset" : 71
    }, {
      "referenceID" : 12,
      "context" : "Rats exposed to a single 6-h inhalation of GO (Han et al., 2015).",
      "startOffset" : 46,
      "endOffset" : 64
    }, {
      "referenceID" : 37,
      "context" : "Mice were administered GP by intratracheal instillation (Mao et al., 2016).",
      "startOffset" : 56,
      "endOffset" : 74
    }, {
      "referenceID" : 26,
      "context" : "The role of surface functionalization in pulmonary inflammation was evaluated using 6 types of GPs: GP, carboxylated GP (COOHGP), Oþ functionalized GP (O2-GP, acylated GP (N2-GP), F functionalized GP (Fc GP), and aminated GP (NH2-GP), intratracheally instilled in rats (Lee et al., 2016).",
      "startOffset" : 269,
      "endOffset" : 287
    }, {
      "referenceID" : 47,
      "context" : "Mice received the pharyngeal aspiration or intrapleural injection of GP (Schinwald et al., 2012).",
      "startOffset" : 72,
      "endOffset" : 96
    }, {
      "referenceID" : 48,
      "context" : "Mice were administered GP by pharyngeal aspiration of GP (Schinwald et al., 2014).",
      "startOffset" : 57,
      "endOffset" : 81
    }, {
      "referenceID" : 28,
      "context" : "Mice underwent the intratracheal instillation of GO and were assessed for acute and subchronic pulmonary toxicity (Li et al., 2013).",
      "startOffset" : 114,
      "endOffset" : 131
    }, {
      "referenceID" : 35,
      "context" : "Stronger inflammatory responses were also reported in the lungs of mice after a single pharyngeal aspiration of larger GO (750e1300 nm) comparedwith smaller GO (50e350 nm) (Ma et al., 2015).",
      "startOffset" : 172,
      "endOffset" : 189
    }, {
      "referenceID" : 20,
      "context" : "Expanded acute toxicity, toxicokinetics, and respiratory/cardiovascular safety pharmacology studies of GP fuctionalized with dextran (DEX-GP), which has the highest level of dispersion achieved for any water-dispersible GP, were performed as a part of the preclinical safety pharmacological evaluation under good laboratory practice (GLP) (Kanakia et al., 2014).",
      "startOffset" : 339,
      "endOffset" : 361
    }, {
      "referenceID" : 46,
      "context" : "Pristine GP, polyethylene glycol functionalized GP (PEG-GP), or COOH-GP was intravenously injected into mice (Sasidharan et al., 2015).",
      "startOffset" : 109,
      "endOffset" : 134
    }, {
      "referenceID" : 29,
      "context" : "GO decreased body weight and increased serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine (CRE) levels 24 h after a single intravenous injection in mice (Li et al., 2014).",
      "startOffset" : 189,
      "endOffset" : 206
    }, {
      "referenceID" : 34,
      "context" : "2 mm) by a single or seven intravenous injections (Liu et al., 2015).",
      "startOffset" : 50,
      "endOffset" : 68
    }, {
      "referenceID" : 63,
      "context" : "A single intravenous injection of GO functionalized with poly 4styrenesulfonate (PSS-GO) caused acute hepatic injury, as evidenced by increased levels of serum AST, ALT, and alkaline phosphatase (ALP) in mice (Wen et al., 2015).",
      "startOffset" : 209,
      "endOffset" : 227
    }, {
      "referenceID" : 24,
      "context" : "Multiple intraperitoneal injections of GO had no acute toxic effects in mice (Kurantowicz et al., 2015) and no acute or subacute toxic effects, except for alterations in oxidative stress parameters in rats (Strojny et al.",
      "startOffset" : 77,
      "endOffset" : 103
    }, {
      "referenceID" : 57,
      "context" : ", 2015) and no acute or subacute toxic effects, except for alterations in oxidative stress parameters in rats (Strojny et al., 2015).",
      "startOffset" : 110,
      "endOffset" : 132
    }, {
      "referenceID" : 35,
      "context" : "Inflammatory responses were systematically and locally induced by multiple intraperitoneal injections and a single intravenous injection of S- (50e350 nm) and L- (750e1300 nm) GO in mice (Ma et al., 2015).",
      "startOffset" : 187,
      "endOffset" : 204
    }, {
      "referenceID" : 67,
      "context" : "Mice received a single intravenous injection of GO, NH2-GO, poly(acrylamide)-fuctionalized GO (PAM-GO), poly(acrylic acid)functionalized GO (PAA-GO), or PEG-GO (Xu et al., 2016).",
      "startOffset" : 160,
      "endOffset" : 177
    }, {
      "referenceID" : 69,
      "context" : "No toxicity was observed in mice after a single intravenous injection of PEG-GO (Yang et al., 2011), a single intraperitoneal injection of GO, PEG-nano GO, -rGO, or -nano rGO (Yang et al.",
      "startOffset" : 80,
      "endOffset" : 99
    }, {
      "referenceID" : 70,
      "context" : ", 2011), a single intraperitoneal injection of GO, PEG-nano GO, -rGO, or -nano rGO (Yang et al., 2013), or a single oral administration of PEG-nano GO (Yang et al.",
      "startOffset" : 83,
      "endOffset" : 102
    }, {
      "referenceID" : 70,
      "context" : ", 2013), or a single oral administration of PEG-nano GO (Yang et al., 2013).",
      "startOffset" : 56,
      "endOffset" : 75
    }, {
      "referenceID" : 74,
      "context" : "Behavioral effects of rGO were determined after repeated oral administration in mice (Zhang et al., 2015) (Table 4).",
      "startOffset" : 85,
      "endOffset" : 105
    }, {
      "referenceID" : 30,
      "context" : "No adverse effects of S-GO (55 nm) or L-GO (238 nm)were observed on male reproduction in mice intravenously and intraperitoneally injected (Liang et al., 2015).",
      "startOffset" : 139,
      "endOffset" : 159
    }, {
      "referenceID" : 66,
      "context" : "Although no reproductive or developmental adverse effect was observed after intravenous injection of SrGO (68 nm) or L-rGO (659 nm) before mating or during early gestation, deaths and abortions were observed after injection of SrGO during late gestation, (Xu et al., 2015).",
      "startOffset" : 255,
      "endOffset" : 272
    }, {
      "referenceID" : 9,
      "context" : "Decreased maternal water consumption containing GO during lactation could have reduced milk production and, thus, growth of the offspring (Fu et al., 2015).",
      "startOffset" : 138,
      "endOffset" : 155
    }, {
      "referenceID" : 46,
      "context" : ", 2013a), GP, COOH-GP, or PEG-GP (Sasidharan et al., 2015) (Table 3).",
      "startOffset" : 33,
      "endOffset" : 58
    }, {
      "referenceID" : 33,
      "context" : "An in vivo micronucleus assay of GO was performed in mice administered GO by repeated intravenous injection (Liu et al., 2013) (Table 4).",
      "startOffset" : 108,
      "endOffset" : 126
    }, {
      "referenceID" : 31,
      "context" : "In rabbits, no significant adverse effects on the ocular system were noted on a single intravitreal injection of hydroxyl (OH-) GP (Lin et al., 2015) or GO (Yan et al.",
      "startOffset" : 131,
      "endOffset" : 149
    }, {
      "referenceID" : 64,
      "context" : "An acute eye irritation test of GO was performed using rabbits according to the OECD guideline (Wu et al., 2016).",
      "startOffset" : 95,
      "endOffset" : 112
    }, {
      "referenceID" : 37,
      "context" : "14C-labeled GP was given to mice by a single intratracheal instillation or oral gavage (Mao et al., 2016).",
      "startOffset" : 87,
      "endOffset" : 105
    }, {
      "referenceID" : 20,
      "context" : "In mice that received a single intravenous injection of DEX-GP, more DEX-GP remained in the heart and liver on day 1 and in the heart on day 30 (Kanakia et al., 2014).",
      "startOffset" : 144,
      "endOffset" : 166
    }, {
      "referenceID" : 28,
      "context" : "After the intratracheal instillation of 125I-labeled GO in mice, the radioactivity in the lung reached a maximum at 10 min and then gradually decreased (Li et al., 2013).",
      "startOffset" : 152,
      "endOffset" : 169
    }, {
      "referenceID" : 58,
      "context" : "After a single intravenous injection of GO in mice, GO was located primarily in the lungs, liver, and spleen, but no GO was observed in the brain (Wang et al., 2011).",
      "startOffset" : 146,
      "endOffset" : 165
    }, {
      "referenceID" : 32,
      "context" : "Mice received a single intravenous injection of 125I-labeled S-GO (100e500 nm) or L-GO (1e5 mm) (Liu et al., 2012).",
      "startOffset" : 96,
      "endOffset" : 114
    }, {
      "referenceID" : 30,
      "context" : "Repeated doses of 125I-labeled S-GO (55 nm) were intravenously or intraperitoneally injected into male mice (Liang et al., 2015).",
      "startOffset" : 108,
      "endOffset" : 128
    }, {
      "referenceID" : 66,
      "context" : "125I-labeled S-rGO (68 nm) distributed mainly in the maternal lung, spleen, and kidney and negligibly in the placenta and fetuses of mice intravenously injected with a single dose on around gestational day (GD) 19 (Xu et al., 2015).",
      "startOffset" : 214,
      "endOffset" : 231
    }, {
      "referenceID" : 63,
      "context" : "DyeCy7-PSS-GO distributed mainly in the liver, with low levels in the bladder within 24 h and, thereafter, gradually accumulated in the liver, lungs, spleen, and bladder in mice after a single intravenous injection (Wen et al., 2015).",
      "startOffset" : 215,
      "endOffset" : 233
    }, {
      "referenceID" : 69,
      "context" : "In mice that received a single intravenous injection of 125Ilabeled PEG-GO, radioactivity was detected at 1 h in many organs including the spleen, liver, stomach, kidney, lung, heart, intestine, bone, thyroid, skin, and muscle, but mainly accumulated in the RES such as the spleen and liver (Yang et al., 2011).",
      "startOffset" : 291,
      "endOffset" : 310
    }, {
      "referenceID" : 70,
      "context" : "Biodistributions of PEG-GO derivatives were determined using 125I-labeled PEG-nano GO, rGO, and nano rGO after intraperitoneal injection and oral administration (Yang et al., 2013).",
      "startOffset" : 161,
      "endOffset" : 180
    }, {
      "referenceID" : 29,
      "context" : "The effect of PEG-coating on the biodistribution of GO was investigated using 125I-labeled GO and 125I-labeled PEG-GO in mice intravenously injected (Li et al., 2014).",
      "startOffset" : 149,
      "endOffset" : 166
    }, {
      "referenceID" : 17,
      "context" : "Although inhalation is the gold standard for determining the potential toxicity of inhalants (Jacobsen et al., 2009; Baisch et al., 2014), only four papers are available on noseonly inhalation toxicity studies of GNMs.",
      "startOffset" : 93,
      "endOffset" : 137
    }, {
      "referenceID" : 51,
      "context" : "The outcomes of inhalation exposure were very similar to those seen after bolus administration, such as intratracheal instillation and pharyngeal aspiration, leading to pulmonary toxicity (Costa et al., 2006; Shvedova et al., 2008; Castranova et al., 2013).",
      "startOffset" : 188,
      "endOffset" : 256
    }, {
      "referenceID" : 37,
      "context" : "Recovery from acute inflammation was observed after intratracheal instillation of GP at 5e50 mg/mouse (Duch et al., 2011; Mao et al., 2016), pharyngeal aspiration of GP at 50 mg/mouse (Schinwald et al.",
      "startOffset" : 102,
      "endOffset" : 139
    }, {
      "referenceID" : 47,
      "context" : ", 2012, 2014), and intrapleural injection of GP at 5 mg/mouse (Schinwald et al., 2012).",
      "startOffset" : 62,
      "endOffset" : 86
    }, {
      "referenceID" : 39,
      "context" : "However, GO is considered more biocompatible than GP due to its greater solubility and dispersibility, which results in it being less toxic to cells (Nezakati et al., 2014).",
      "startOffset" : 149,
      "endOffset" : 172
    }, {
      "referenceID" : 37,
      "context" : "However, airway exposure to GNMs did not induce clear systemic toxicity even though labeled GNMs were detected in the major organs after intratracheal instillation of GP (Mao et al., 2016) and GO (Li et al.",
      "startOffset" : 170,
      "endOffset" : 188
    }, {
      "referenceID" : 20,
      "context" : ", 2013a), DEX-GP (Kanakia et al., 2014), COOH-GP (Sasidharan et al.",
      "startOffset" : 17,
      "endOffset" : 39
    }, {
      "referenceID" : 58,
      "context" : ", 2015), GO (Wang et al., 2011; Zhang et al., 2011b; Liu et al., 2015; Xu et al., 2016), and PSS-GO (Wen et al.",
      "startOffset" : 12,
      "endOffset" : 87
    }, {
      "referenceID" : 34,
      "context" : ", 2015), GO (Wang et al., 2011; Zhang et al., 2011b; Liu et al., 2015; Xu et al., 2016), and PSS-GO (Wen et al.",
      "startOffset" : 12,
      "endOffset" : 87
    }, {
      "referenceID" : 67,
      "context" : ", 2015), GO (Wang et al., 2011; Zhang et al., 2011b; Liu et al., 2015; Xu et al., 2016), and PSS-GO (Wen et al.",
      "startOffset" : 12,
      "endOffset" : 87
    }, {
      "referenceID" : 63,
      "context" : ", 2016), and PSS-GO (Wen et al., 2015) predominantly caused pulmonary inflammation.",
      "startOffset" : 20,
      "endOffset" : 38
    }, {
      "referenceID" : 57,
      "context" : "The intraperitoneal injection of GO (Qu et al., 2013b; Strojny et al., 2015) and PEG-GO (Chong et al.",
      "startOffset" : 36,
      "endOffset" : 76
    }, {
      "referenceID" : 46,
      "context" : "GNMs largely accumulated in the lungs after intravenous injection of GP and COOH-GP (Sasidharan et al., 2015), and GO (Wang et al.",
      "startOffset" : 84,
      "endOffset" : 109
    }, {
      "referenceID" : 30,
      "context" : "Higher accumulations of GO (Liang et al., 2015) and PEG-GO and rGO (Yang et al.",
      "startOffset" : 27,
      "endOffset" : 47
    }, {
      "referenceID" : 70,
      "context" : ", 2015) and PEG-GO and rGO (Yang et al., 2013) were observed in the spleen and liver after intraperitoneal injection.",
      "startOffset" : 27,
      "endOffset" : 46
    }, {
      "referenceID" : 74,
      "context" : "One study revealed that oral rGO was absorbed from the gastrointestinal tract, distributed in many organs, and altered mouse behavior (Zhang et al., 2015).",
      "startOffset" : 134,
      "endOffset" : 154
    }, {
      "referenceID" : 37,
      "context" : "Another two studies on oral administration showed that GP (Mao et al., 2016), GO, PEG-GO, and PEG-rGO (Yang et al.",
      "startOffset" : 58,
      "endOffset" : 76
    }, {
      "referenceID" : 70,
      "context" : ", 2016), GO, PEG-GO, and PEG-rGO (Yang et al., 2013) are in a form that is difficult to absorb form the gastrointestinal tract.",
      "startOffset" : 33,
      "endOffset" : 52
    }, {
      "referenceID" : 70,
      "context" : "These three GO derivatives did not show toxicological effects (Yang et al., 2013).",
      "startOffset" : 62,
      "endOffset" : 81
    }, {
      "referenceID" : 30,
      "context" : "No testicular toxicity was reported after the intravenous injection of GO (Qu et al., 2013a; Liang et al., 2015), GP, COOH-GP, or PEG-GP (Sasidharan et al.",
      "startOffset" : 74,
      "endOffset" : 112
    }, {
      "referenceID" : 46,
      "context" : ", 2015), GP, COOH-GP, or PEG-GP (Sasidharan et al., 2015) or after intraperitoneal injection of GO (Liang et al.",
      "startOffset" : 32,
      "endOffset" : 57
    }, {
      "referenceID" : 30,
      "context" : ", 2015) or after intraperitoneal injection of GO (Liang et al., 2015).",
      "startOffset" : 49,
      "endOffset" : 69
    }, {
      "referenceID" : 9,
      "context" : "No clear developmental toxicity of oral GO (Fu et al., 2015) or intravenous rGO (Xu et al.",
      "startOffset" : 43,
      "endOffset" : 60
    }, {
      "referenceID" : 66,
      "context" : ", 2015) or intravenous rGO (Xu et al., 2015) or behavioral toxicity of oral rGO (Zhang et al.",
      "startOffset" : 27,
      "endOffset" : 44
    }, {
      "referenceID" : 74,
      "context" : ", 2015) or behavioral toxicity of oral rGO (Zhang et al., 2015) was also reported.",
      "startOffset" : 43,
      "endOffset" : 63
    }, {
      "referenceID" : 46,
      "context" : "No accumulation of GP, COOH-GP, or PEG-GP (Sasidharan et al., 2015) and negligible accumulation of GO (Liang et al.",
      "startOffset" : 42,
      "endOffset" : 67
    }, {
      "referenceID" : 30,
      "context" : ", 2015) and negligible accumulation of GO (Liang et al., 2015) in the testes were reported.",
      "startOffset" : 42,
      "endOffset" : 62
    }, {
      "referenceID" : 66,
      "context" : "Negligible transplacental transfer of rGO (Xu et al., 2015) and very low accumulations of GO (Zhang et al.",
      "startOffset" : 42,
      "endOffset" : 59
    }, {
      "referenceID" : 74,
      "context" : ", 2011b) and rGO (Zhang et al., 2015) in the brain were also reported.",
      "startOffset" : 17,
      "endOffset" : 37
    }, {
      "referenceID" : 5,
      "context" : "Positive results have been reported in in vitro genotoxicity studies of GP (Chatterjee et al., 2016), GO (Qiao et al.",
      "startOffset" : 75,
      "endOffset" : 100
    }, {
      "referenceID" : 0,
      "context" : ", 2016), rGO (Akhavan et al., 2012), and GQDs (Wang et al.",
      "startOffset" : 13,
      "endOffset" : 35
    }, {
      "referenceID" : 56,
      "context" : "The main mechanism for toxicity of NMs is currently proposed to be generation of ROS resulting in oxidative stress, which stimulate inflammatory responses (Stone et al., 2009; Møller et al., 2010).",
      "startOffset" : 155,
      "endOffset" : 196
    }, {
      "referenceID" : 18,
      "context" : "The generation of intracellular ROS in target cells is a potentially initial mechanism for toxicity of GNMs (Jastrzębska et al., 2012; Lalwani et al., 2016).",
      "startOffset" : 108,
      "endOffset" : 156
    }, {
      "referenceID" : 25,
      "context" : "The generation of intracellular ROS in target cells is a potentially initial mechanism for toxicity of GNMs (Jastrzębska et al., 2012; Lalwani et al., 2016).",
      "startOffset" : 108,
      "endOffset" : 156
    }, {
      "referenceID" : 27,
      "context" : "The accumulation of intracellular ROS is the main characteristic of oxidative stress, so the detection of ROS generation reflects the intracellular oxidative stress status (Li et al., 2012).",
      "startOffset" : 172,
      "endOffset" : 189
    }, {
      "referenceID" : 56,
      "context" : ", ROS) and antioxidant defense mechanisms of the body (Stone et al., 2009).",
      "startOffset" : 54,
      "endOffset" : 74
    }, {
      "referenceID" : 28,
      "context" : "The intratracheal instillation of GO decreased activity of antioxidants, SOD and GSH-PX, suggesting that oxidative stress is associated with GO-induced acute lung injury in mice (Li et al., 2013).",
      "startOffset" : 178,
      "endOffset" : 195
    }, {
      "referenceID" : 64,
      "context" : "GSH inhibited eye toxicity induced by GO in rats (Wu et al., 2016).",
      "startOffset" : 49,
      "endOffset" : 66
    }, {
      "referenceID" : 74,
      "context" : "The oral administration of rGO slightly decreased serum SOD levels in mice (Zhang et al., 2015).",
      "startOffset" : 75,
      "endOffset" : 95
    }, {
      "referenceID" : 34,
      "context" : "However, oxidative stress is not dominant toxicological mechanism of intravenous GNMs, because GO did not change GSH or MDA levels in the liver, spleen, or lungs (Liu et al., 2015) and rGO increased levels of GSH and decreased levels of MDA in the rat liver after intraperitoneal injection, suggesting the lack of oxidative stress in the liver (Strojny et al.",
      "startOffset" : 162,
      "endOffset" : 180
    }, {
      "referenceID" : 57,
      "context" : ", 2015) and rGO increased levels of GSH and decreased levels of MDA in the rat liver after intraperitoneal injection, suggesting the lack of oxidative stress in the liver (Strojny et al., 2015).",
      "startOffset" : 171,
      "endOffset" : 193
    }, {
      "referenceID" : 14,
      "context" : "Furthermore, direct interaction between the cell membrane and GO was proposed as the toxicological mechanism of GO because the cytotoxicity of GO was markedly mitigated when it was incubated with serum due to the high protein absorption ability of GO (Hu et al., 2011).",
      "startOffset" : 251,
      "endOffset" : 268
    }, {
      "referenceID" : 25,
      "context" : "GPwith sharp edges can induce direct physical damage, leading to membrane destabilization and loss of cell integrity (Lalwani et al., 2016).",
      "startOffset" : 117,
      "endOffset" : 139
    }, {
      "referenceID" : 45,
      "context" : "physical toxicity or the absorption of biological molecules, leading to indirect toxicity (Sanchez et al., 2012; Bianco, 2013).",
      "startOffset" : 90,
      "endOffset" : 126
    }, {
      "referenceID" : 25,
      "context" : "The shape and size can influence their cellular uptake characteristics, functional groups can alter their interactions with proteins, biomolecules, and micronutrients, the dispersed status of the test suspension can influence toxicity, and surface coating with biocompatible moieties can mitigate toxicity (Lalwani et al., 2016).",
      "startOffset" : 306,
      "endOffset" : 328
    }, {
      "referenceID" : 6,
      "context" : "Long fibers are more slowly cleared as they cannot be easily enclosed by macrophages, leading to frustrated phagocytosis, and this concept has been accepted as a keymechanism for the toxicity of long fibers (Donaldson et al., 2010; Schinwald et al., 2012).",
      "startOffset" : 207,
      "endOffset" : 255
    }, {
      "referenceID" : 47,
      "context" : "Long fibers are more slowly cleared as they cannot be easily enclosed by macrophages, leading to frustrated phagocytosis, and this concept has been accepted as a keymechanism for the toxicity of long fibers (Donaldson et al., 2010; Schinwald et al., 2012).",
      "startOffset" : 207,
      "endOffset" : 255
    }, {
      "referenceID" : 47,
      "context" : "This structureactivity relationship seen with the long fiber-like structure does not take sheet/platelet shape particles into account and, therefore, has to be reconsidered in the light of new materials (Schinwald et al., 2012).",
      "startOffset" : 203,
      "endOffset" : 227
    }, {
      "referenceID" : 47,
      "context" : "Clear signs of frustrated phagocytosis were observed in pleural macrophages after intrapleural injection of GP (Schinwald et al., 2012).",
      "startOffset" : 111,
      "endOffset" : 135
    }, {
      "referenceID" : 46,
      "context" : "The biodegradation of tissue-bound PEG-GP and COOH-GP was also suggested (Sasidharan et al., 2015).",
      "startOffset" : 73,
      "endOffset" : 98
    }, {
      "referenceID" : 35,
      "context" : "Regardless of exposure routes, L-GO induced stronger inflammatory responses than S-GO (Ma et al., 2015).",
      "startOffset" : 86,
      "endOffset" : 103
    }, {
      "referenceID" : 34,
      "context" : "After multiple intravenous injections, more severe toxicity was caused by L-GO than S-GO, and hepatic inflammatory infiltration was observed after multiple injections of S-GO (Liu et al., 2015).",
      "startOffset" : 175,
      "endOffset" : 193
    }, {
      "referenceID" : 29,
      "context" : "Furthermore, it is suggested that the clearance of GO from the kidney is size-dependent and GO of small sizes is quickly eliminated via the renal route (Zhang et al., 2011b; Li et al., 2014).",
      "startOffset" : 152,
      "endOffset" : 190
    }, {
      "referenceID" : 11,
      "context" : "Most GNMs tend to aggregate in physiological solutions due to electrostatic charges and nonspecific binding to protein, and therefore, the development of functionalized GNMs has improved their solubility and biocompatibility, and reduced toxicity (Guo and Mei, 2014).",
      "startOffset" : 247,
      "endOffset" : 266
    }, {
      "referenceID" : 46,
      "context" : "GP and COOH-GP, but not PEG-GP, caused histopathological changes in the major organs (Sasidharan et al., 2015).",
      "startOffset" : 85,
      "endOffset" : 110
    }, {
      "referenceID" : 29,
      "context" : "PEG-GO lessened GO-induced toxic effects (Li et al., 2014).",
      "startOffset" : 41,
      "endOffset" : 58
    }, {
      "referenceID" : 52,
      "context" : "Regarding the pulmonary toxicity, the dispersion status of SWCNTs has also been shown to influence the deposition and biological effect (Mercer et al., 2008; Shvedova et al., 2014).",
      "startOffset" : 136,
      "endOffset" : 180
    }, {
      "referenceID" : 52,
      "context" : "Dispersed SWCNTs can be deposited in the distal alveoli, rapidly migrate and be incorporated into the alveolar walls, and induce more potent inflammatogenic and interstitial fibrotic reactions in the absence of granuloma formation (Mercer et al., 2008; Shvedova et al., 2014).",
      "startOffset" : 231,
      "endOffset" : 275
    }, {
      "referenceID" : 45,
      "context" : "It is very important to provide data on characterization of GNMs used in toxicological studies because lateral size is a key variable in cell uptake, layer number affects deposition and surface area, and surface chemistry affects absorption and dispersibility (Sanchez et al., 2012).",
      "startOffset" : 260,
      "endOffset" : 282
    }, {
      "referenceID" : 26,
      "context" : "Lung fibrosis was induced by airway exposure to GP (Duch et al., 2011; Wang et al., 2015a; Lee et al., 2016) and GO (Wang et al.",
      "startOffset" : 51,
      "endOffset" : 108
    }, {
      "referenceID" : 15,
      "context" : "Inflammation and the resulting fibrosis have been considered as significant risk factors in pulmonary carcinogenesis (Hubbard et al., 2000; Shvedova et al., 2008).",
      "startOffset" : 117,
      "endOffset" : 162
    }, {
      "referenceID" : 51,
      "context" : "Inflammation and the resulting fibrosis have been considered as significant risk factors in pulmonary carcinogenesis (Hubbard et al., 2000; Shvedova et al., 2008).",
      "startOffset" : 117,
      "endOffset" : 162
    } ],
    "year" : 2017,
    "abstractText" : "We summarized the findings of toxicity studies on graphene-based nanomaterials (GNMs) in laboratory mammals. The inhalation of graphene (GP) and graphene oxide (GO) induced only minimal pulmonary toxicity. Bolus airway exposure to GP and GO caused acute and subacute pulmonary inflammation. Largesized GO (L-GO) was more toxic than small-sized GO (S-GO). Intratracheally administered GP passed through the air-blood barrier into the blood and intravenous GO distributed mainly in the lungs, liver, and spleen. S-GO and L-GO mainly accumulated in the liver and lungs, respectively. Limited information showed the potential behavioral, reproductive, and developmental toxicity and genotoxicity of GNMs. There are indications that oxidative stress and inflammation may be involved in the toxicity of GNMs. The surface reactivity, size, and dispersion status of GNMs play an important role in the induction of toxicity and biodistribution of GNMs. Although this review paper provides initial information on the potential toxicity of GNMs, data are still very limited, especially when taking into account the many different types of GNMs and their potential modifications. To fill the data gap, further studies should be performed using laboratory mammals exposed using the route and dose anticipated for human exposure scenarios. © 2017 Elsevier Inc. All rights reserved.",
    "creator" : "Elsevier"
  }
}